EP2231221B1 - Wound management - Google Patents
Wound management Download PDFInfo
- Publication number
- EP2231221B1 EP2231221B1 EP08856265.7A EP08856265A EP2231221B1 EP 2231221 B1 EP2231221 B1 EP 2231221B1 EP 08856265 A EP08856265 A EP 08856265A EP 2231221 B1 EP2231221 B1 EP 2231221B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- wound
- drape
- inlet port
- delivery tube
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003795 chemical substances by application Substances 0.000 claims description 43
- 239000012530 fluid Substances 0.000 claims description 27
- 238000007789 sealing Methods 0.000 claims description 11
- 239000012790 adhesive layer Substances 0.000 claims description 5
- 230000000149 penetrating effect Effects 0.000 claims description 2
- 206010052428 Wound Diseases 0.000 description 130
- 208000027418 Wounds and injury Diseases 0.000 description 130
- 239000002699 waste material Substances 0.000 description 46
- 238000002560 therapeutic procedure Methods 0.000 description 17
- 210000000416 exudates and transudate Anatomy 0.000 description 15
- 239000000463 material Substances 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- 230000002262 irrigation Effects 0.000 description 9
- 238000003973 irrigation Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 8
- 238000009581 negative-pressure wound therapy Methods 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 239000000853 adhesive Substances 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000001070 adhesive effect Effects 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 238000000465 moulding Methods 0.000 description 5
- 230000035876 healing Effects 0.000 description 4
- 239000007937 lozenge Substances 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 230000001012 protector Effects 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 230000000887 hydrating effect Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 230000003584 silencer Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010011409 Cross infection Diseases 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101000836649 Homo sapiens Selenoprotein V Proteins 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- 102100027056 Selenoprotein V Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical group 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011340 continuous therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- -1 painkillers Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M3/00—Medical syringes, e.g. enemata; Irrigators
- A61M3/02—Enemata; Irrigators
- A61M3/0279—Cannula; Nozzles; Tips; their connection means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/71—Suction drainage systems
- A61M1/77—Suction-irrigation systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/80—Suction pumps
- A61M1/81—Piston pumps, e.g. syringes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/80—Suction pumps
- A61M1/81—Piston pumps, e.g. syringes
- A61M1/815—Piston pumps, e.g. syringes the barrel serving as aspiration container, e.g. in a breast pump
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/84—Drainage tubes; Aspiration tips
- A61M1/85—Drainage tubes; Aspiration tips with gas or fluid supply means, e.g. for supplying rinsing fluids or anticoagulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
- A61M1/92—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing with liquid supply means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
- A61M1/98—Containers specifically adapted for negative pressure wound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M3/00—Medical syringes, e.g. enemata; Irrigators
- A61M3/02—Enemata; Irrigators
- A61M3/0204—Physical characteristics of the irrigation fluid, e.g. conductivity or turbidity
- A61M3/0208—Physical characteristics of the irrigation fluid, e.g. conductivity or turbidity before use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M3/00—Medical syringes, e.g. enemata; Irrigators
- A61M3/02—Enemata; Irrigators
- A61M3/0204—Physical characteristics of the irrigation fluid, e.g. conductivity or turbidity
- A61M3/0212—Physical characteristics of the irrigation fluid, e.g. conductivity or turbidity after use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M3/00—Medical syringes, e.g. enemata; Irrigators
- A61M3/02—Enemata; Irrigators
- A61M3/0204—Physical characteristics of the irrigation fluid, e.g. conductivity or turbidity
- A61M3/0216—Pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M3/00—Medical syringes, e.g. enemata; Irrigators
- A61M3/02—Enemata; Irrigators
- A61M3/0204—Physical characteristics of the irrigation fluid, e.g. conductivity or turbidity
- A61M3/022—Volume; Flow rate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/71—Suction drainage systems
- A61M1/74—Suction control
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
- A61M1/96—Suction control thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
- A61M1/98—Containers specifically adapted for negative pressure wound therapy
- A61M1/982—Containers specifically adapted for negative pressure wound therapy with means for detecting level of collected exudate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
- A61M1/98—Containers specifically adapted for negative pressure wound therapy
- A61M1/984—Containers specifically adapted for negative pressure wound therapy portable on the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3331—Pressure; Flow
- A61M2205/3334—Measuring or controlling the flow rate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M3/00—Medical syringes, e.g. enemata; Irrigators
- A61M3/02—Enemata; Irrigators
- A61M3/0202—Enemata; Irrigators with electronic control means or interfaces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M3/00—Medical syringes, e.g. enemata; Irrigators
- A61M3/02—Enemata; Irrigators
- A61M3/0233—Enemata; Irrigators characterised by liquid supply means, e.g. from pressurised reservoirs
- A61M3/0254—Enemata; Irrigators characterised by liquid supply means, e.g. from pressurised reservoirs the liquid being pumped
- A61M3/0262—Enemata; Irrigators characterised by liquid supply means, e.g. from pressurised reservoirs the liquid being pumped manually, e.g. by squeezing a bulb
Definitions
- the present invention relates to apparatus and a method for the application of topical negative pressure (TNP) therapy to wounds.
- TNP topical negative pressure
- the present invention relates to a method and apparatus for delivering an agent such as medicament or hydrating fluid through or under a drape covering a wound site.
- TNP therapy assists in the closure and healing of wounds by reducing tissue oedema; encouraging blood flow and granulation of tissue; removing excess exudates and may reduce bacterial load and thus, infection to the wound. Furthermore, TNP therapy permits less outside disturbance of the wound and promotes more rapid healing.
- this invention describes the treatment of a wound by the application of topical negative pressure (TNP) therapy for aspirating the wound together with the further provision of additional fluid for irrigating and/or cleansing the wound, which fluid, comprising both wound exudates and irrigation fluid, is then drawn off by the aspiration means and circulated through means for separating the beneficial materials therein from deleterious materials.
- TNP topical negative pressure
- the materials which are beneficial to wound healing are recirculated through the wound dressing and those materials deleterious to wound healing are discarded to a waste collection bag or vessel.
- the above apparatus and methods are generally only applicable to a patient when hospitalised as the apparatus is complex, needing people having specialist knowledge in how to operate and maintain the apparatus, and also relatively heavy and bulky, not being adapted for easy mobility outside of a hospital environment by a patient, for example.
- GB-A-2 307 180 describes a portable TNP therapy unit which may be carried by a patient clipped to belt or harness. It will be appreciated however that there are limitations as to how parameters associated with a wound site can be maintained.
- WO 01/37922 discloses a control system for use with a bandage under negative pressure such that fluid can be introduced into a wound.
- WO 2005/115523 and WO 2006/114638 disclose a wound dressing apparatus. Further WO 2006/114638 discloses an apparatus for aspirating, irrigating and/or cleansing a wound with at least one pipe to allow irrigation and/or aspiration of the wound.
- agents such as painkillers, anti-biotics and/or wound irrigation
- apparatus for delivering at least one agent to a wound site comprising the steps of:
- the invention is comprised in part of an overall apparatus for the provision of TNP therapy to a patient in almost any environment.
- the apparatus is lightweight, may be mains or battery powered by a rechargeable battery pack contained within a device (henceforth, the term “device” is used to connote a unit which may contain all of the control, power supply, power supply recharging, electronic indicator means and means for initiating and sustaining aspiration functions to a wound and any further necessary functions of a similar nature).
- the apparatus may provide for an extended period of operation on battery power and in the home, for example, the device may be connected to the mains by a charger unit whilst still being used and operated by the patient.
- the overall apparatus of which the present invention is a part comprises: a dressing covering the wound and sealing at least an open end of an aspiration conduit to a cavity formed over the wound by the dressing; an aspiration tube comprising at least one lumen therethrough leading from the wound dressing to a waste material canister for collecting and holding wound exudates/waste material prior to disposal; and, a power, control and aspiration initiating and sustaining device associated with the waste canister.
- the dressing covering the wound may be any type of dressing normally employed with TNP therapy and, in very general terms, may comprise, for example, a semi-permeable, flexible, self-adhesive drape material, as is known in the dressings art, to cover the wound and seal with surrounding sound tissue to create a sealed cavity or void over the wound.
- a porous barrier and support member in the cavity between the wound bed and the covering material to enable an even vacuum distribution to be achieved over the area of the wound.
- the porous barrier and support member being, for example, a gauze, a foam, an inflatable bag or known wound contact type material resistant to crushing under the levels of vacuum created and which permits transfer of wound exudates across the wound area to the aspiration conduit sealed to the flexible cover drape over the wound.
- the aspiration conduit may be a plain flexible tube, for example, having a single lumen therethrough and made from a plastics material compatible with raw tissue, for example.
- the aspiration conduit may have a plurality of lumens therethrough to achieve specific objectives relating to the invention.
- a portion of the tube sited within the sealed cavity over the wound may have a structure to enable continued aspiration and evacuation of wound exudates without becoming constricted or blocked even at the higher levels of the negative pressure range envisaged.
- the negative pressure range for the apparatus embodying the present invention may be between about -50 mmHg and -200 mmHg (note that these pressures are relative to normal ambient atmospheric pressure thus, -200 mmHg would be about 560 mmHg in practical terms).
- the pressure range may be between about -75 mmHg and -150 mmHg.
- a pressure range of upto -75 mmHg, upto -80 mmHg or over -80 mmHg can be used.
- a pressure range of below - 75 mmHg could be used.
- a pressure range of over -100 mmHg could be used or over -150 mmHg.
- the aspiration conduit at its distal end remote from the dressing may be attached to the waste canister at an inlet port or connector.
- the device containing the means for initiating and sustaining aspiration of the wound/dressing may be situated between the dressing and waste canister, however, in a preferred embodiment of the apparatus embodying the present invention, the device may aspirate the wound/dressing via the canister thus, the waste canister may preferably be sited between the wound/dressing and device.
- the aspiration conduit at the waste material canister end may preferably be bonded to the waste canister to prevent inadvertent detachment when being caught on an obstruction, for example.
- the canister may be a plastics material moulding or a composite unit comprising a plurality of separate mouldings.
- the canister may aptly be translucent or transparent in order to visually determine the extent of filling with exudates.
- the canister and device may in some embodiments provide automatic warning of imminent canister full condition and may also provide means for cessation of aspiration when the canister reaches the full condition.
- the canister may be provided with filters to prevent the exhaust of liquids and odours therefrom and also to prevent the expulsion of bacteria into the atmosphere.
- filters may comprise a plurality of filters in series.
- suitable filters may comprise hydrophobic filters of 0.2 ⁇ m pore size, for example, in respect of sealing the canister against bacteria expulsion and 1 ⁇ m against liquid expulsion.
- the filters may be sited at an upper portion of the waste canister in normal use, that is when the apparatus is being used or carried by a patient the filters are in an upper position and separated from the exudate liquid in the waste canister by gravity. Furthermore, such an orientation keeps the waste canister outlet or exhaust exit port remote from the exudate surface.
- the waste canister may be filled with an absorbent gel such as ISOLYSEL (trade mark), for example, as an added safeguard against leakage of the canister when full and being changed and disposed of.
- an absorbent gel such as ISOLYSEL (trade mark)
- Added advantages of a gel matrix within the exudate storing volume of the waste canister are that it prevents excessive movement, such as slopping, of the liquid, minimises bacterial growth and minimises odours.
- the waste canister may also be provided with suitable means to prevent leakage thereof both when detached from the device unit and also when the aspiration conduit is detached from the wound site/dressing.
- the canister may have suitable means to prevent emptying by a user (without tools or damage to the canister) such that a full or otherwise end-of-life canister may only be disposed of with waste fluid still contained.
- the device and waste canister may have mutually complementary means for connecting a device unit to a waste canister whereby the aspiration means in the device unit automatically connects to an evacuation port on the waste canister such that there is a continuous aspiration path from the wound site/dressing to an exhaust port on the device.
- the exhaust port from the fluid path through the apparatus is provided with filter means to prevent offensive odours from being ejected into the atmosphere.
- the device unit comprises an aspirant pump; means for monitoring pressure applied by the aspirant pump; a flowmeter to monitor fluid flow through the aspirant pump; a control system which controls the aspirant pump in response to signals from sensors such as the pressure monitoring means and the flowmeter, for example, and which control system also controls a power management system with regard to an on-board battery pack and the charging thereof and lastly a user interface system whereby various functions of the device such as pressure level set point, for example, may be adjusted (including stopping and starting of the apparatus) by a user.
- the device unit may contain all of the above features within a single unified casing.
- the device unit contains the majority of the intrinsic equipment cost therein ideally it will also be able to survive impact, tolerate cleaning in order to be reusable by other patients.
- the aspiration means may be able to apply a maximum pressure drop of at least -200 mmHg to a wound site/dressing.
- the apparatus is capable of maintaining a predetermined negative pressure even under conditions where there is a small leak of air into the system and a high exudate flow.
- the pressure control system may prevent the minimum pressure achieved from exceeding for example -200 mmHg so as not to cause undue patient discomfort.
- the pressure required may be set by the user at a number of discreet levels such as -50, - 75, -100, -125, -150, -175 mmHg, for example, depending upon the needs of the wound in question and the advice of a clinician.
- suitable pressure ranges in use may be from -25 to -80 mmHg, or -50 to -76 mmHg, or -50 to -75 mmHg as examples.
- the control system may also advantageously be able to maintain the set pressure within a tolerance band of +/- 10 mmHg of the set point for 95% of the time the apparatus is operating given that leakage and exudation rates are within expected or normal levels.
- control system may trigger alarm means such as a flashing light, buzzer or any other suitable means when various abnormal conditions apply such as, for example: pressure outside set value by a large amount due to a gross leak of air into system; duty on the aspiration pump too high due to a relatively smaller leakage of air into the system; pressure differential between wound site and pump is too high due, for example, to a blockage or waste canister full.
- alarm means such as a flashing light, buzzer or any other suitable means when various abnormal conditions apply such as, for example: pressure outside set value by a large amount due to a gross leak of air into system; duty on the aspiration pump too high due to a relatively smaller leakage of air into the system; pressure differential between wound site and pump is too high due, for example, to a blockage or waste canister full.
- the apparatus of the present invention may be provided with a carry case and suitable support means such as a shoulder strap or harness, for example.
- the carry case may be adapted to conform to the shape of the apparatus comprised in the joined together device and waste canister.
- the carry case may be provided with a bottom opening flap to permit the waste canister to be changed without complete removal of the apparatus form the carry case.
- the carry case may be provided with an aperture covered by a displaceable flap to enable user access to a keypad for varying the therapy applied by the apparatus.
- FIG. 1 shows a generalised schematic view of an apparatus 10 of a portable topical negative pressure (TNP) system.
- TNP topical negative pressure
- FIG. 1 shows a generalised schematic view of an apparatus 10 of a portable topical negative pressure (TNP) system.
- TNP topical negative pressure
- FIG. 1 shows a generalised schematic view of an apparatus 10 of a portable topical negative pressure (TNP) system.
- TNP topical negative pressure
- the apparatus comprises an aspiration conduit 12 operably and an outer surface thereof at one end sealingly attached to a dressing 14.
- the dressing 14 will not be further described here other than to say that it is formed in a known manner from well know materials to those skilled in the dressings art to create a sealed cavity over and around a wound to be treated by TNP therapy with the apparatus of the present invention.
- the aspiration conduit has an in-line connector 16 comprising connector portions 18, 20 intermediate its length between the dressing 14 and a waste canister 22.
- the aspiration conduit between the connector portion 20 and the canister 22 is denoted by a different reference numeral 24 although the fluid path through conduit portions 12 and 24 to the waste canister is continuous.
- the connector portions 18, 20 join conduit portions 12, 24 in a leak-free but disconnectable manner.
- the waste canister 22 is provided with filters 26 which prevent the escape via an exit port 28 of liquid and bacteria from the waste canister.
- the filters may comprise a 1 ⁇ m hydrophobic liquid filter and a 0.2 ⁇ m bacteria filter such that all liquid and bacteria is confined to an interior waste collecting volume of the waste canister 22.
- the exit port 28 of the waste canister 22 mates with an entry/suction port 30 of a device unit 32 by means of mutually sealing connector portions 34, 36 which engage and seal together automatically when the waste canister 22 is attached to the device unit 32, the waste canister 22 and device unit 32 being held together by catch assemblies 38, 40.
- the device unit 32 comprises an aspirant pump 44, an aspirant pressure monitor 46 and an aspirant flowmeter 48 operably connected together.
- the aspiration path takes the aspirated fluid which in the case of fluid on the exit side of exit port 28 is gaseous through a silencer system 50 and a final filter 52 having an activated charcoal matrix which ensures that no odours escape with the gas exhausted from the device 32 via an exhaust port 54.
- the filter 52 material also serves as noise reducing material to enhance the effect of the silencer system 50.
- the device 32 also contains a battery pack 56 to power the apparatus which battery pack also powers the control system 60 which controls a user interface system 62 controlled via a keypad (not shown) and the aspiration pump 44 via signals from sensors 46, 48.
- a power management system 66 is also provided which controls power from the battery pack 56, the recharging thereof and the power requirements of the aspirant pump 44 and other electrically operated components.
- An electrical connector 68 is provided to receive a power input jack 70 from a SELV power supply 72 connected to a mains supply 74 when the user of the apparatus or the apparatus itself is adjacent a convenient mains power socket.
- FIG 2 shows a similar schematic representation to Figure 1 but shows the fluid paths in more detail.
- the wound exudate is aspirated from the wound site/dressing 14 via the conduit 12, the two connector portions 18, 20 and the conduit 24 into the waste canister 22.
- the waste canister 22 comprises a relatively large volume 80 in the region of 500ml into which exudate from the wound is drawn by the aspiration system at an entry port 82.
- the fluid 84 drawn into the canister volume 80 is a mixture of both air drawn into the dressing 14 via the semi-permeable adhesive sealing drape (not shown) and liquid 86 in the form of wound exudates.
- the volume 80 within the canister is also at a lowered pressure and the gaseous element 88 of the aspirated fluids is exhausted from the canister volume 80 via the filters 26 and the waste canister exhaust exit port 28 as bacteria-free gas. From the exit port 28 of the waste canister to the final exhaust port 54 the fluid is gaseous only.
- FIG. 3 shows a schematic diagram showing only the device portion of the apparatus and the power paths in the device of the apparatus embodying the present invention.
- Power is provided mainly by the battery pack 56 when the user is outside their home or workplace, for example, however, power may also be provided by an external mains 74 supplied charging unit 72 which when connected to the device 32 by the socket 68 is capable of both operating the device and recharging the battery pack 56 simultaneously.
- the power management system 66 is included so as to be able to control power of the TNP system.
- the TNP system is a rechargeable, battery powered system but is capable of being run directly from mains electricity as will be described hereinafter more fully with respect to the further figures. If disconnected from the mains the battery has enough stored charge for approximately 8 hours of use in normal conditions.
- batteries having other associated life times between recharge can be utilised. For example batteries providing less than 8 hours or greater than 8 hours can be used.
- the device When connected to the mains the device will run off the mains power and will simultaneously recharge the battery if depleted from portable use. The exact rate of battery recharge will depend on the load on the TNP system. For example, if the wound is very large or there is a significant leak, battery recharge will take longer than if the wound is small and well sealed.
- FIG. 4 shows the device 32 part of the apparatus embodying the present invention and the data paths employed in the control system for control of the aspirant pump and other features of the apparatus.
- a key purpose of the TNP system is to apply negative pressure wound therapy. This is accomplished via the pressure control system which includes the pump and a pump control system.
- the pump applies negative pressure; the pressure control system gives feedback on the pressure at the pump head to the control system; the pump control varies the pump speed based on the difference between the target pressure and the actual pressure at the pump head.
- the pump is controlled by an auxiliary control system.
- the pump is from time to time allowed to "free-wheel” during its duty cycle by turning off the voltage applied to it.
- the spinning motor causes a "back electro-motive force" or BEMF to be generated. This BEMF can be monitored and can be used to provide an accurate measure of pump speed. The speed can thus be adjusted more accurately than can prior art pump systems.
- actual pressure at a wound site is not measured but the difference between a measured pressure (at the pump) and the wound pressure is minimised by the use of large filters and large bore tubes wherever practical. If the pressure control measures that the pressure at the pump head is greater than a target pressure (closer to atmospheric pressure) for a period of time, the device sends an alarm and displays a message alerting the user to a potential problem such as a leak.
- a flow meter may be positioned after the pump and is used to detect when a canister is full or the tube has become blocked. If the flow falls below a certain threshold, the device sounds an alarm and displays a message alerting a user to the potential blockage or full canister.
- the preferred embodiment is of generally oval shape in plan and comprises a device unit 202 and a waste canister 204 connected together by catch arrangements 206.
- the device unit 202 has a liquid crystal display (LCD) 208, which gives text based feedback on the wound therapy being applied, and a membrane keypad 210, the LCD being visible through the membrane of the keypad to enable a user to adjust or set the therapy to be applied to the wound (not shown).
- LCD liquid crystal display
- the device has a lower, generally transverse face 212 in the centre of which is a spigot 214 which forms the suction/entry port 216 to which the aspiration means (to be described below) are connected within the device unit.
- the lower edge of the device unit is provided with a rebated peripheral male mating face 218 which engages with a co-operating peripheral female formation 220 on an upper edge of the waste canister 204 (see Figures 8 and 9 ).
- clips 222 hinged to the canister 204 have an engaging finger (not shown) which co-operates with formations in recesses 226 in the body of the device unit.
- the casing 230 of the device unit is of largely "clamshell" construction comprising front and back mouldings 232, 234, respectively and left-hand and right-hand side inserts 236, 238.
- a central chassis 240 which is fastened to an internal moulded structural member 242 and which chassis acts as a mounting for the electrical circuitry and components and also retains the battery pack 246 and aspiration pump unit 248.
- Various tubing items 250, 252, 254 connect the pump unit 248 and suction/entry port 216 to a final gaseous exhaust via a filter 290.
- Figure 8 shows a partially sectioned side elevation of the apparatus 200, the partial section being around the junction between the device unit 202 and the waste canister 204, a cross section of which is shown at Figure 9 .
- Figure 9 show the rebated edge 218 of the male formation on the device unit co-operating with the female portion 220 defined by an upstanding flange 260 around the top face 262 of the waste canister 204.
- the spigot 214 which has an "O" ring seal 264 therearound sealingly engages with a cylindrical tube portion 266 formed around an exhaust/exit port 268 in the waste canister.
- the spigot 214 of the device is not rigidly fixed to the device casing but is allowed to "float" or move in its location features in the casing to permit the spigot 214 and seal 264 to move to form the best seal with the bore of the cylindrical tube portion 266 on connection of the waste canister to the device unit.
- the waste canister 204 in Figure 9 is shown in an upright orientation much as it would be when worn by a user. Thus, any exudate 270 would be in the bottom of the internal volume of waste receptacle portion 272.
- An aspiration conduit 274 is permanently affixed to an entry port spigot 278 defining an entry port 280 to receive fluid aspirated from a wound (not shown) via the conduit 274.
- Filter members 282 comprising a 0.2 ⁇ m filter and 284 comprising a 1 ⁇ m filter are located by a filter retainer moulding 286 adjacent a top closure member or bulkhead 288 the filter members preventing any liquid or bacteria from being drawn out of the exhaust exit port 268 into the pump and aspiration path through to an exhaust and filter unit 290 which is connected to a casing outlet moulding at 291 via an exhaust tube (not shown) in casing side piece 236.
- the side pieces 236, 238 are provided with recesses 292 having support pins 294 therein to locate a carrying strap (not shown) for use by the patient.
- the side pieces 230 and canister 204 are also provided with features which prevent the canister and device from exhibiting a mutual "wobble" when connected together.
- Ribs (not shown) extending between the canister top closure member 288 and the inner face 300 of the upstanding flange 260 locate in grooves 302 in the device sidewalls when canister and device are connected.
- the casing 230 also houses all of the electrical equipment and control and power management features, the functioning of which was described briefly with respect to Figures 3 and 4 hereinabove.
- the side piece 238 is provided with a socket member 298 to receive a charging jack from an external mains powered battery charger (both not shown).
- FIG. 10 illustrates a way in which bacterial load of a wound can be reduced or removed according to embodiments of the present invention. It will be appreciated that embodiments of the present invention can also be utilised to prevent wounds drying out and/or relieve localised pain and/or introduce anti-biotics and/or provide wound irrigation at a wound site.
- a wound site 1000 includes a wound bed 1001 in a skin layer 1002 of a patient.
- a drain 1003 is secured to a distal end of the aspiration conduit 12 via a connector.
- the drain is sealed to the dressing such that a reduced pressure can be maintained at the wound using a drape or other such sealing means.
- a gauze 1004 or other filler mechanism may be used in the wound site to pad out the area under the drape 14.
- a generally T-shaped delivery tube 1005 extends through the drape 14.
- the projection of the delivery tube through the drape can be achieved either by providing a dressing with an inlet port (not shown) sized to accommodate the delivery tube diameter or by pinching the drape 14 around the delivery tube during dressing of the wound site.
- the delivery tube 1005 includes an agent inlet port 1006 through which agent can be introduced.
- embodiments of the present invention can be used to deliver a wide variety of agents to the wound site.
- embodiments of the present invention can deliver powdered or fluid medicament and/or pain relief medicament and/or anti-biotics and/or saline solution and/or hydrating fluid and/or biologically active agents and/or growth factors and/or enzymes and/or anti inflammatories.
- Embodiments of the present invention can also be utilised to introduce a mixture of agents.
- the agent is introduced at the inlet valve 1006 it passes along the delivery tube through the drape to the wound site, entering the wound site through an outlet 1007.
- the delivery tube 1005 is also provided with a removable cap 1008 which can be resealably sealed on the end of the delivery tube.
- a removable cap 1008 which can be resealably sealed on the end of the delivery tube.
- the cap 1008 is removed to reveal a filter 1009 which is provided to allow air to fill the wound as desired. The air allows the injection port to be flushed and helps the removal of large volumes of fluid from the wound.
- agent can be introduced to the wound site using a syringe 1010 which contains a predetermined quantity of the agent to be introduced.
- the syringe is placed onto the side tube of the delivery tube with the required solution and then a pinch clamp 1011 or other such inlet valve is released.
- the cap 1008 is removed and fluid or dry agent then injected into the wound.
- NPWT can then be applied to the wound. Alternatively the NPWT may continue whilst the agent is introduced.
- Figure 11 illustrates an alternative embodiment of the present invention in which agent is introduced to a wound site from a reservoir 1100 containing the agent 1020 such as hydrating fluid.
- the agent 1020 can be released from the reservoir by a mechanical time release system 1101 arranged to periodically open a valve 1102 to release agent into the delivery tube.
- a mechanical time release system 1101 arranged to periodically open a valve 1102 to release agent into the delivery tube.
- any other type of release system could be utilised for the reservoir 1010.
- an electrical time release system could be utilised or the delivery tube 1005 could be connected to the container via an orifice or number of orifices each having a size predetermined so as to effectively drip agent into the wound bed region.
- the valve may be kept open continuously.
- Figure 12 illustrates an alternative embodiment of the present invention in which the delivery tube 1200 has a substantial disc like base section 1201 from which an upstanding tube 1202 extends.
- a side tube 1203 branches from the upstanding tube 1202 and has an agent inlet port 1204 controlled by an inlet valve 1205. It will be appreciated that agents can be introduced through the inlet port 1205 and inlet valve 1205 as described with the previous embodiments.
- the port 1204 may be protected by a septum not shown.
- the upwardly extending delivery tube 1202 has a filter 1206 in an upper housing 1207.
- An opening 1208 allows air to enter the delivery tube where an air inlet valve 1209 is opened.
- a cap (not shown) may resealably seal 1208 in the delivery tube.
- a lower surface 1210 of the delivery tube body 1201 carries an adhesive layer 1211 which is covered by protector paper 1212.
- the protector paper 1212 may be peeled away to reveal the adhesive as will be described herein below.
- a penetrating portion 1213 of the delivery tube extends below a low surface of the disc like body 1201.
- the protrusion extends below this lower surface a sufficient distance so that penetration of a drape 14 can occur when the delivery tube is mounted on a sealed dressing.
- the delivery tube shown in Figure 12 provides a port which can be attached to a TNP dressing to provide access for agents to the wound.
- a TNP dressing to provide access for agents to the wound.
- the sealing layer of the TNP dressing referred to here as a drape
- the protector layer 1212 is removed exposing the pressure sensitive adhesive layer.
- the device is then positioned such that the protrusion aligns with the pierced hole on the sealing means and a force applied to ensure that a good seal is made with the adhesive.
- the delivery tube may be made of any substantially rigid material but aptly a flexible polymeric material having a typical sure hardness 50-70A eg silicone, PVC, polyurethane or the like may be utilised.
- the inlet 1204 may include a fitting to allow attachment of a device such as a syringe or reservoir as will be appreciated by those skilled in the art.
- FIG 13 illustrates an alternative embodiment of the present invention similar in many respects to that shown in Figure 12 but in which the lower base portion 1300 includes a central substantially conical region 1301 which flares outwardly into a thinner disc-like region 1302.
- the thinness of the disc region 1302 means that the delivery tube can be secured between two sealing drapes of a dressing.
- the top drape is illustrated as drape 1305 which is a disc with central hole.
- To this end protector paper 1303 is provided to cover a lower surface of an adhesive layer 1304 which is adhered at an a proximal end to an upper surface to the disc-like portion 1302 of the delivery tube.
- An upper surface of the adhesive layer 1304 is covered by the drape 1305.
- the drape 1305 may have a further film (not shown) on top of it to strengthen the drape 1305 during assembly with the dressing. The film can be removed once the drape 1305 is firmly in place.
- a small hole is first punctured in a lower sealing layer with the peeling paper being removed and then the delivery tube urged onto the lower drape so that the protrusion 1213 extends through the drape.
- the delivery tube is secured to the lower drape by the lower surface of the adhesive layer 1304.
- FIG. 14 illustrates an alternative embodiment of the present invention in which a delivery tube 1400 has a lozenge shaped base section 1401 from which an upstanding tube 1402 extends.
- Figure 15 illustrates how the delivery tube 1400 illustrated in Figure 14 can be located between a main drape 1501 and auxiliary drape 1502.
- the delivery tube of this embodiment tends to lie sideways against a wound site.
- the use of the main drape 1501 and auxiliary drape 1502, which form a flap 1503, means that the delivery tube and portions of the main and auxiliary drape are movable. This makes the covering easier to put on and can be more comfortable to a patient.
- the tube will lie substantially flat so that accidental disturbance of the delivery tube is kept to a minimum. This is particularly helpful when the delivery tube is used continuously as part of a drip process.
- the auxiliary drape 1502 is adhered to a target surface close to the wound site 1000.
- An end region 1504 of the auxiliary drape 1502 is folded back to form a fold line 1505.
- the upper surface 1506 is adhesive and the lozenge portion of the delivery tube 1402 can be adhered to this upper surface.
- the main drape 1501 is laid over the wound site covering the end region 1504 of the auxiliary drape.
- a lower surface 1507 of the main drape is adhesive so that the main drape and auxiliary drape can be pinched together around the lozenge base portion of the delivery tube 1400.
- the flap 1503 is formed which can hingedly move around the hinge line 1505.
- passageways can be formed through the lozenge section of the delivery tube 1400 to provide further input and output access to the wound site.
- the delivery tube may be connected directly to an outlet of a saline drip so that the wound bed may continuously be irrigated.
- fluid may be drawn out from the wound bed region for sampling.
- a passage through the drape 14 or under the drape means that from time to time fluid or dry agent may be introduced into a wound site without needing to move the dressing.
- from time to time embodiments of the present invention allow wound fluid to be drawn out of the wound bed again without the need to disturb the drape 14 covering the wound dressing thus obviating certain disadvantages associated with prior art dressings.
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- General Health & Medical Sciences (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Fluid Mechanics (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Surgery (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- External Artificial Organs (AREA)
Description
- The present invention relates to apparatus and a method for the application of topical negative pressure (TNP) therapy to wounds. In particular, but not exclusively, the present invention relates to a method and apparatus for delivering an agent such as medicament or hydrating fluid through or under a drape covering a wound site.
- There is much prior art available relating to the provision of apparatus and methods of use thereof for the application of TNP therapy to wounds together with other therapeutic processes intended to enhance the effects of the TNP therapy. Examples of such prior art include those listed and briefly described below.
- TNP therapy assists in the closure and healing of wounds by reducing tissue oedema; encouraging blood flow and granulation of tissue; removing excess exudates and may reduce bacterial load and thus, infection to the wound. Furthermore, TNP therapy permits less outside disturbance of the wound and promotes more rapid healing.
- In our co-pending International patent application,
WO 2004/037334 , apparatus, a wound dressing and a method for aspirating, irrigating and cleansing wounds are described. In very general terms, this invention describes the treatment of a wound by the application of topical negative pressure (TNP) therapy for aspirating the wound together with the further provision of additional fluid for irrigating and/or cleansing the wound, which fluid, comprising both wound exudates and irrigation fluid, is then drawn off by the aspiration means and circulated through means for separating the beneficial materials therein from deleterious materials. The materials which are beneficial to wound healing are recirculated through the wound dressing and those materials deleterious to wound healing are discarded to a waste collection bag or vessel. - In our co-pending International patent application,
WO 2005/04670 WO 2004/037334 with regard to the aspiration, irrigation and cleansing of the wound, however, it further includes the important additional step of providing heating means to control the temperature of that beneficial material being returned to the wound site/dressing so that it is at an optimum temperature, for example, to have the most efficacious therapeutic effect on the wound. - In our co-pending International patent application,
WO 2005/105180 , apparatus and a method for the aspiration, irrigation and/or cleansing of wounds are described. Again, in very general terms, this document describes similar apparatus to the two previously mentioned documents hereinabove but with the additional step of providing means for the supply and application of physiologically active agents to the wound site/dressing to promote wound healing. - However, the above apparatus and methods are generally only applicable to a patient when hospitalised as the apparatus is complex, needing people having specialist knowledge in how to operate and maintain the apparatus, and also relatively heavy and bulky, not being adapted for easy mobility outside of a hospital environment by a patient, for example.
- Some patients having relatively less severe wounds which do not require continuous hospitalisation, for example, but whom nevertheless would benefit from the prolonged application of TNP therapy, could be treated at home or at work subject to the availability of an easily portable and maintainable TNP therapy apparatus.
-
GB-A-2 307 180 - In general it is known that the bacterial load of wounds can increase over time and that wounds can also dry out whilst under negative pressure wound therapy. This is particularly so when using conventional wound dressings such as ALLEVYN (trademark) At present a way of reducing wound/tissue infection is by regularly changing dressings which are located over a wound site. This has an impact on the patient since changing dressing can lead to patient discomfort, increased cost associated with the replacement dressings themselves and can increase the chances of patient to patient infection.
- It is also known that from time to time it is advantageous to deliver one or more agents such as pain relief medicament, anti-biotics, wound irrigation etc to a wound site. With known techniques a dressing or drape kept over the wound site to prevent infection must be removed prior to delivery of the agent with a new drape/dressing being required known techniques a dressing or drape kept over the wound site to prevent infection must be removed prior to delivery of the agent with a new drape/dressing being required subsequent to introduction of the agent. Again this can lead to patient discomfort, increases costs and increases likelihood of cross infection.
-
US6398767 andWO03/073970 -
WO 01/37922 -
WO 2005/115523 andWO 2006/114638 disclose a wound dressing apparatus. FurtherWO 2006/114638 discloses an apparatus for aspirating, irrigating and/or cleansing a wound with at least one pipe to allow irrigation and/or aspiration of the wound. - It is an aim of the present invention to at least partly mitigate the above-mentioned problems.
- It is an aim of embodiments of the present invention to provide a method and apparatus which permits one or more agents such as painkillers, anti-biotics and/or wound irrigation to be introduced at a wound site without having to remove/replace a drape/dressing covering the wound site.
- It is an aim of embodiments of the present invention to provide a method and apparatus which is able to automatically deliver agent continuous or at predetermined time intervals to a wound site.
- It is an aim of embodiments of the present invention to provide a method and apparatus which permits a user to quickly and efficiently deliver a highly precise dose of medicament or other such agent to a wound site.
- The invention is as claimed in the claims.
- According to a first aspect of the present invention there is provided apparatus for delivering at least one agent to a wound site, comprising the steps of:
- providing a delivery tube having an outlet at a wound site;
- covering the wound site with a drape; and
- introducing agent at an agent inlet port of the delivery tube, agent passing along the delivery tube through or under the drape to the wound site.
- The invention is comprised in part of an overall apparatus for the provision of TNP therapy to a patient in almost any environment. The apparatus is lightweight, may be mains or battery powered by a rechargeable battery pack contained within a device (henceforth, the term "device" is used to connote a unit which may contain all of the control, power supply, power supply recharging, electronic indicator means and means for initiating and sustaining aspiration functions to a wound and any further necessary functions of a similar nature). When outside the home, for example, the apparatus may provide for an extended period of operation on battery power and in the home, for example, the device may be connected to the mains by a charger unit whilst still being used and operated by the patient.
- The overall apparatus of which the present invention is a part comprises: a dressing covering the wound and sealing at least an open end of an aspiration conduit to a cavity formed over the wound by the dressing; an aspiration tube comprising at least one lumen therethrough leading from the wound dressing to a waste material canister for collecting and holding wound exudates/waste material prior to disposal; and, a power, control and aspiration initiating and sustaining device associated with the waste canister.
- The dressing covering the wound may be any type of dressing normally employed with TNP therapy and, in very general terms, may comprise, for example, a semi-permeable, flexible, self-adhesive drape material, as is known in the dressings art, to cover the wound and seal with surrounding sound tissue to create a sealed cavity or void over the wound. There may aptly be a porous barrier and support member in the cavity between the wound bed and the covering material to enable an even vacuum distribution to be achieved over the area of the wound. The porous barrier and support member being, for example, a gauze, a foam, an inflatable bag or known wound contact type material resistant to crushing under the levels of vacuum created and which permits transfer of wound exudates across the wound area to the aspiration conduit sealed to the flexible cover drape over the wound.
- The aspiration conduit may be a plain flexible tube, for example, having a single lumen therethrough and made from a plastics material compatible with raw tissue, for example. However, the aspiration conduit may have a plurality of lumens therethrough to achieve specific objectives relating to the invention. A portion of the tube sited within the sealed cavity over the wound may have a structure to enable continued aspiration and evacuation of wound exudates without becoming constricted or blocked even at the higher levels of the negative pressure range envisaged.
- It is envisaged that the negative pressure range for the apparatus embodying the present invention may be between about -50 mmHg and -200 mmHg (note that these pressures are relative to normal ambient atmospheric pressure thus, -200 mmHg would be about 560 mmHg in practical terms). Aptly, the pressure range may be between about -75 mmHg and -150 mmHg. Alternatively a pressure range of upto -75 mmHg, upto -80 mmHg or over -80 mmHg can be used. Also aptly a pressure range of below - 75 mmHg could be used. Alternatively a pressure range of over -100 mmHg could be used or over -150 mmHg.
- The aspiration conduit at its distal end remote from the dressing may be attached to the waste canister at an inlet port or connector. The device containing the means for initiating and sustaining aspiration of the wound/dressing may be situated between the dressing and waste canister, however, in a preferred embodiment of the apparatus embodying the present invention, the device may aspirate the wound/dressing via the canister thus, the waste canister may preferably be sited between the wound/dressing and device.
- The aspiration conduit at the waste material canister end may preferably be bonded to the waste canister to prevent inadvertent detachment when being caught on an obstruction, for example.
- The canister may be a plastics material moulding or a composite unit comprising a plurality of separate mouldings. The canister may aptly be translucent or transparent in order to visually determine the extent of filling with exudates. However, the canister and device may in some embodiments provide automatic warning of imminent canister full condition and may also provide means for cessation of aspiration when the canister reaches the full condition.
- The canister may be provided with filters to prevent the exhaust of liquids and odours therefrom and also to prevent the expulsion of bacteria into the atmosphere. Such filters may comprise a plurality of filters in series. Examples of suitable filters may comprise hydrophobic filters of 0.2µm pore size, for example, in respect of sealing the canister against bacteria expulsion and 1 µm against liquid expulsion.
- Aptly, the filters may be sited at an upper portion of the waste canister in normal use, that is when the apparatus is being used or carried by a patient the filters are in an upper position and separated from the exudate liquid in the waste canister by gravity. Furthermore, such an orientation keeps the waste canister outlet or exhaust exit port remote from the exudate surface.
- Aptly the waste canister may be filled with an absorbent gel such as ISOLYSEL (trade mark), for example, as an added safeguard against leakage of the canister when full and being changed and disposed of. Added advantages of a gel matrix within the exudate storing volume of the waste canister are that it prevents excessive movement, such as slopping, of the liquid, minimises bacterial growth and minimises odours.
- The waste canister may also be provided with suitable means to prevent leakage thereof both when detached from the device unit and also when the aspiration conduit is detached from the wound site/dressing.
- The canister may have suitable means to prevent emptying by a user (without tools or damage to the canister) such that a full or otherwise end-of-life canister may only be disposed of with waste fluid still contained.
- The device and waste canister may have mutually complementary means for connecting a device unit to a waste canister whereby the aspiration means in the device unit automatically connects to an evacuation port on the waste canister such that there is a continuous aspiration path from the wound site/dressing to an exhaust port on the device.
- Aptly, the exhaust port from the fluid path through the apparatus is provided with filter means to prevent offensive odours from being ejected into the atmosphere.
- In general terms the device unit comprises an aspirant pump; means for monitoring pressure applied by the aspirant pump; a flowmeter to monitor fluid flow through the aspirant pump; a control system which controls the aspirant pump in response to signals from sensors such as the pressure monitoring means and the flowmeter, for example, and which control system also controls a power management system with regard to an on-board battery pack and the charging thereof and lastly a user interface system whereby various functions of the device such as pressure level set point, for example, may be adjusted (including stopping and starting of the apparatus) by a user. The device unit may contain all of the above features within a single unified casing.
- In view of the fact that the device unit contains the majority of the intrinsic equipment cost therein ideally it will also be able to survive impact, tolerate cleaning in order to be reusable by other patients.
- In terms of pressure capability the aspiration means may be able to apply a maximum pressure drop of at least -200 mmHg to a wound site/dressing. The apparatus is capable of maintaining a predetermined negative pressure even under conditions where there is a small leak of air into the system and a high exudate flow.
- The pressure control system may prevent the minimum pressure achieved from exceeding for example -200 mmHg so as not to cause undue patient discomfort. The pressure required may be set by the user at a number of discreet levels such as -50, - 75, -100, -125, -150, -175 mmHg, for example, depending upon the needs of the wound in question and the advice of a clinician. Thus suitable pressure ranges in use may be from -25 to -80 mmHg, or -50 to -76 mmHg, or -50 to -75 mmHg as examples. The control system may also advantageously be able to maintain the set pressure within a tolerance band of +/- 10 mmHg of the set point for 95% of the time the apparatus is operating given that leakage and exudation rates are within expected or normal levels.
- Aptly, the control system may trigger alarm means such as a flashing light, buzzer or any other suitable means when various abnormal conditions apply such as, for example: pressure outside set value by a large amount due to a gross leak of air into system; duty on the aspiration pump too high due to a relatively smaller leakage of air into the system; pressure differential between wound site and pump is too high due, for example, to a blockage or waste canister full.
- The apparatus of the present invention may be provided with a carry case and suitable support means such as a shoulder strap or harness, for example. The carry case may be adapted to conform to the shape of the apparatus comprised in the joined together device and waste canister. In particular, the carry case may be provided with a bottom opening flap to permit the waste canister to be changed without complete removal of the apparatus form the carry case.
- The carry case may be provided with an aperture covered by a displaceable flap to enable user access to a keypad for varying the therapy applied by the apparatus.
- In order that the present invention may be more fully understood, examples will now be described by way of illustration only with reference to the accompanying drawings, of which:
-
Figure 1 shows a generalised schematic block diagram showing a general view of an apparatus and the constituent apparatus features thereof; -
Figure 2 shows a similar generalised schematic block diagram toFigure 1 and showing fluid paths therein; -
Figure 3 shows a generalised schematic block diagram similar toFigure 1 but of a device unit only and showing power paths for the various power consuming/producing features of the apparatus; -
Figure 4 shows a similar generalised schematic block diagram toFigure 3 of the device unit and showing control system data paths for controlling the various functions and components of the apparatus; -
Figure 5 shows a perspective view of an apparatus; -
Figure 6 shows a perspective view of an assembled device unit of the apparatus ofFigure 5 ; -
Figure 7 shows an exploded view of the device unit ofFigure 6 ; -
Figure 8 shows a partially sectioned side elevation view through the interface between a waste canister and device unit of the apparatus; -
Figure 9 shows a cross section through a waste canister of the apparatus ofFigures 5 to 8 ; -
Figure 10 illustrates a wound site; -
Figure 11 illustrates an alternative wound site; -
Figure 12 illustrates how a delivery tube can be secured to a drape; -
Figure 13 illustrates a delivery tube securable between two drapes; -
Figure 14 illustrates a delivery tube; and -
Figure 15 illustrates the delivery tube shown inFigure 14 located at a wound site. - Referring now to
Figures 1 to 4 of the drawings and where the same or similar features are denoted by common reference numerals. -
Figure 1 shows a generalised schematic view of anapparatus 10 of a portable topical negative pressure (TNP) system. It will be understood that embodiments of the present invention are generally applicable to use in such a TNP system. Briefly, negative pressure wound therapy assists in the closure and healing of many forms of "hard to heal" wounds by reducing tissue oedema; encouraging blood flow and granular tissue formation; removing excess exudate and may reduce bacterial load (and, therefore, infection). In addition the therapy allows for less disturbance of a wound leading to more rapid healing. The TNP system is detailed further hereinafter but in summary includes a portable body including a canister and a device with the device capable of providing an extended period of continuous therapy within at least a one year life span. The system is connected to a patient via a length of tubing with an end of the tubing operably secured to a wound dressing on the patient. - More particularly, as shown in
Figure 1 , the apparatus comprises anaspiration conduit 12 operably and an outer surface thereof at one end sealingly attached to adressing 14. The dressing 14 will not be further described here other than to say that it is formed in a known manner from well know materials to those skilled in the dressings art to create a sealed cavity over and around a wound to be treated by TNP therapy with the apparatus of the present invention. The aspiration conduit has an in-line connector 16 comprisingconnector portions waste canister 22. The aspiration conduit between theconnector portion 20 and thecanister 22 is denoted by adifferent reference numeral 24 although the fluid path throughconduit portions connector portions join conduit portions waste canister 22 is provided withfilters 26 which prevent the escape via anexit port 28 of liquid and bacteria from the waste canister. The filters may comprise a 1µm hydrophobic liquid filter and a 0.2µm bacteria filter such that all liquid and bacteria is confined to an interior waste collecting volume of thewaste canister 22. Theexit port 28 of thewaste canister 22 mates with an entry/suction port 30 of adevice unit 32 by means of mutually sealingconnector portions waste canister 22 is attached to thedevice unit 32, thewaste canister 22 anddevice unit 32 being held together bycatch assemblies device unit 32 comprises anaspirant pump 44, an aspirant pressure monitor 46 and anaspirant flowmeter 48 operably connected together. The aspiration path takes the aspirated fluid which in the case of fluid on the exit side ofexit port 28 is gaseous through asilencer system 50 and afinal filter 52 having an activated charcoal matrix which ensures that no odours escape with the gas exhausted from thedevice 32 via anexhaust port 54. Thefilter 52 material also serves as noise reducing material to enhance the effect of thesilencer system 50. Thedevice 32 also contains abattery pack 56 to power the apparatus which battery pack also powers thecontrol system 60 which controls auser interface system 62 controlled via a keypad (not shown) and theaspiration pump 44 via signals fromsensors power management system 66 is also provided which controls power from thebattery pack 56, the recharging thereof and the power requirements of theaspirant pump 44 and other electrically operated components. Anelectrical connector 68 is provided to receive apower input jack 70 from aSELV power supply 72 connected to amains supply 74 when the user of the apparatus or the apparatus itself is adjacent a convenient mains power socket. -
Figure 2 shows a similar schematic representation toFigure 1 but shows the fluid paths in more detail. The wound exudate is aspirated from the wound site/dressing 14 via theconduit 12, the twoconnector portions conduit 24 into thewaste canister 22. Thewaste canister 22 comprises a relativelylarge volume 80 in the region of 500ml into which exudate from the wound is drawn by the aspiration system at an entry port 82. The fluid 84 drawn into thecanister volume 80 is a mixture of both air drawn into the dressing 14 via the semi-permeable adhesive sealing drape (not shown) and liquid 86 in the form of wound exudates. Thevolume 80 within the canister is also at a lowered pressure and thegaseous element 88 of the aspirated fluids is exhausted from thecanister volume 80 via thefilters 26 and the waste canisterexhaust exit port 28 as bacteria-free gas. From theexit port 28 of the waste canister to thefinal exhaust port 54 the fluid is gaseous only. -
Figure 3 shows a schematic diagram showing only the device portion of the apparatus and the power paths in the device of the apparatus embodying the present invention. Power is provided mainly by thebattery pack 56 when the user is outside their home or workplace, for example, however, power may also be provided by anexternal mains 74 supplied chargingunit 72 which when connected to thedevice 32 by thesocket 68 is capable of both operating the device and recharging thebattery pack 56 simultaneously. Thepower management system 66 is included so as to be able to control power of the TNP system. The TNP system is a rechargeable, battery powered system but is capable of being run directly from mains electricity as will be described hereinafter more fully with respect to the further figures. If disconnected from the mains the battery has enough stored charge for approximately 8 hours of use in normal conditions. It will be appreciated that batteries having other associated life times between recharge can be utilised. For example batteries providing less than 8 hours or greater than 8 hours can be used. When connected to the mains the device will run off the mains power and will simultaneously recharge the battery if depleted from portable use. The exact rate of battery recharge will depend on the load on the TNP system. For example, if the wound is very large or there is a significant leak, battery recharge will take longer than if the wound is small and well sealed. -
Figure 4 shows thedevice 32 part of the apparatus embodying the present invention and the data paths employed in the control system for control of the aspirant pump and other features of the apparatus. A key purpose of the TNP system is to apply negative pressure wound therapy. This is accomplished via the pressure control system which includes the pump and a pump control system. The pump applies negative pressure; the pressure control system gives feedback on the pressure at the pump head to the control system; the pump control varies the pump speed based on the difference between the target pressure and the actual pressure at the pump head. In order to improve accuracy of pump speed and hence provide smoother and more accurate application of the negative pressure at a wound site, the pump is controlled by an auxiliary control system. The pump is from time to time allowed to "free-wheel" during its duty cycle by turning off the voltage applied to it. The spinning motor causes a "back electro-motive force" or BEMF to be generated. This BEMF can be monitored and can be used to provide an accurate measure of pump speed. The speed can thus be adjusted more accurately than can prior art pump systems. - According to embodiments of the present invention, actual pressure at a wound site is not measured but the difference between a measured pressure (at the pump) and the wound pressure is minimised by the use of large filters and large bore tubes wherever practical. If the pressure control measures that the pressure at the pump head is greater than a target pressure (closer to atmospheric pressure) for a period of time, the device sends an alarm and displays a message alerting the user to a potential problem such as a leak.
- In addition to pressure control a separate flow control system can be provided. A flow meter may be positioned after the pump and is used to detect when a canister is full or the tube has become blocked. If the flow falls below a certain threshold, the device sounds an alarm and displays a message alerting a user to the potential blockage or full canister.
- Referring now to
Figures 5 to 9 which show various views and cross sections of a preferred embodiment ofapparatus 200 embodying the present invention. The preferred embodiment is of generally oval shape in plan and comprises adevice unit 202 and awaste canister 204 connected together bycatch arrangements 206. Thedevice unit 202 has a liquid crystal display (LCD) 208, which gives text based feedback on the wound therapy being applied, and amembrane keypad 210, the LCD being visible through the membrane of the keypad to enable a user to adjust or set the therapy to be applied to the wound (not shown). The device has a lower, generallytransverse face 212 in the centre of which is aspigot 214 which forms the suction/entry port 216 to which the aspiration means (to be described below) are connected within the device unit. The lower edge of the device unit is provided with a rebated peripheralmale mating face 218 which engages with a co-operating peripheralfemale formation 220 on an upper edge of the waste canister 204 (seeFigures 8 and 9 ). On each side of thedevice 202,clips 222 hinged to thecanister 204 have an engaging finger (not shown) which co-operates with formations inrecesses 226 in the body of the device unit. FromFigure 7 it may be seen that thecasing 230 of the device unit is of largely "clamshell" construction comprising front andback mouldings casing 230 is acentral chassis 240 which is fastened to an internal mouldedstructural member 242 and which chassis acts as a mounting for the electrical circuitry and components and also retains thebattery pack 246 andaspiration pump unit 248.Various tubing items pump unit 248 and suction/entry port 216 to a final gaseous exhaust via afilter 290.Figure 8 shows a partially sectioned side elevation of theapparatus 200, the partial section being around the junction between thedevice unit 202 and thewaste canister 204, a cross section of which is shown atFigure 9 . Theses views show therebated edge 218 of the male formation on the device unit co-operating with thefemale portion 220 defined by anupstanding flange 260 around thetop face 262 of thewaste canister 204. When the waste canister is joined to the device unit, thespigot 214 which has an "O"ring seal 264 therearound sealingly engages with acylindrical tube portion 266 formed around an exhaust/exit port 268 in the waste canister. Thespigot 214 of the device is not rigidly fixed to the device casing but is allowed to "float" or move in its location features in the casing to permit thespigot 214 and seal 264 to move to form the best seal with the bore of thecylindrical tube portion 266 on connection of the waste canister to the device unit. Thewaste canister 204 inFigure 9 is shown in an upright orientation much as it would be when worn by a user. Thus, anyexudate 270 would be in the bottom of the internal volume ofwaste receptacle portion 272. Anaspiration conduit 274 is permanently affixed to anentry port spigot 278 defining anentry port 280 to receive fluid aspirated from a wound (not shown) via theconduit 274.Filter members 282 comprising a 0.2µm filter and 284 comprising a 1µm filter are located by afilter retainer moulding 286 adjacent a top closure member orbulkhead 288 the filter members preventing any liquid or bacteria from being drawn out of theexhaust exit port 268 into the pump and aspiration path through to an exhaust andfilter unit 290 which is connected to a casing outlet moulding at 291 via an exhaust tube (not shown) incasing side piece 236. Theside pieces recesses 292 having support pins 294 therein to locate a carrying strap (not shown) for use by the patient. Theside pieces 230 andcanister 204 are also provided with features which prevent the canister and device from exhibiting a mutual "wobble" when connected together. Ribs (not shown) extending between the canistertop closure member 288 and theinner face 300 of theupstanding flange 260 locate ingrooves 302 in the device sidewalls when canister and device are connected. Thecasing 230 also houses all of the electrical equipment and control and power management features, the functioning of which was described briefly with respect toFigures 3 and4 hereinabove. Theside piece 238 is provided with asocket member 298 to receive a charging jack from an external mains powered battery charger (both not shown). - It will be appreciated that the bacterial load of wounds can increase over time and that wounds can, unless evasive action is taken, dry out whilst under negative pressure wound therapy (NPWT). This is so when using conventional wound dressings.
Figure 10 illustrates a way in which bacterial load of a wound can be reduced or removed according to embodiments of the present invention. It will be appreciated that embodiments of the present invention can also be utilised to prevent wounds drying out and/or relieve localised pain and/or introduce anti-biotics and/or provide wound irrigation at a wound site. - As illustrated in
figure 10 awound site 1000 includes awound bed 1001 in askin layer 1002 of a patient. Adrain 1003 is secured to a distal end of theaspiration conduit 12 via a connector. The drain is sealed to the dressing such that a reduced pressure can be maintained at the wound using a drape or other such sealing means. Agauze 1004 or other filler mechanism may be used in the wound site to pad out the area under thedrape 14. - A generally T-shaped
delivery tube 1005 extends through thedrape 14. The projection of the delivery tube through the drape can be achieved either by providing a dressing with an inlet port (not shown) sized to accommodate the delivery tube diameter or by pinching thedrape 14 around the delivery tube during dressing of the wound site. Thedelivery tube 1005 includes anagent inlet port 1006 through which agent can be introduced. - It will be appreciated that embodiments of the present invention can be used to deliver a wide variety of agents to the wound site. For example, but not exclusively, embodiments of the present invention can deliver powdered or fluid medicament and/or pain relief medicament and/or anti-biotics and/or saline solution and/or hydrating fluid and/or biologically active agents and/or growth factors and/or enzymes and/or anti inflammatories. Embodiments of the present invention can also be utilised to introduce a mixture of agents. When the agent is introduced at the
inlet valve 1006 it passes along the delivery tube through the drape to the wound site, entering the wound site through anoutlet 1007. - The
delivery tube 1005 is also provided with aremovable cap 1008 which can be resealably sealed on the end of the delivery tube. When an agent is to be introduced to the wound site thecap 1008 is removed to reveal afilter 1009 which is provided to allow air to fill the wound as desired. The air allows the injection port to be flushed and helps the removal of large volumes of fluid from the wound. - As illustrated in
Figure 10 agent can be introduced to the wound site using asyringe 1010 which contains a predetermined quantity of the agent to be introduced. The syringe is placed onto the side tube of the delivery tube with the required solution and then apinch clamp 1011 or other such inlet valve is released. Thecap 1008 is removed and fluid or dry agent then injected into the wound. When a predetermined quantity of the agent has been introduced the cap may be replaced back on the filter and the pinch clamp reapplied. The syringe may then be removed. NPWT can then be applied to the wound. Alternatively the NPWT may continue whilst the agent is introduced. -
Figure 11 illustrates an alternative embodiment of the present invention in which agent is introduced to a wound site from areservoir 1100 containing theagent 1020 such as hydrating fluid. Theagent 1020 can be released from the reservoir by a mechanicaltime release system 1101 arranged to periodically open avalve 1102 to release agent into the delivery tube. It will be appreciated by those skilled in the art that any other type of release system could be utilised for thereservoir 1010. For example but not exhaustively an electrical time release system could be utilised or thedelivery tube 1005 could be connected to the container via an orifice or number of orifices each having a size predetermined so as to effectively drip agent into the wound bed region. Alternatively the valve may be kept open continuously. -
Figure 12 illustrates an alternative embodiment of the present invention in which thedelivery tube 1200 has a substantial disc likebase section 1201 from which anupstanding tube 1202 extends. Aside tube 1203 branches from theupstanding tube 1202 and has anagent inlet port 1204 controlled by aninlet valve 1205. It will be appreciated that agents can be introduced through theinlet port 1205 andinlet valve 1205 as described with the previous embodiments. Theport 1204 may be protected by a septum not shown. - Likewise the upwardly extending
delivery tube 1202 has afilter 1206 in anupper housing 1207. Anopening 1208 allows air to enter the delivery tube where anair inlet valve 1209 is opened. A cap (not shown) may resealably seal 1208 in the delivery tube. - A
lower surface 1210 of thedelivery tube body 1201 carries anadhesive layer 1211 which is covered byprotector paper 1212. Theprotector paper 1212 may be peeled away to reveal the adhesive as will be described herein below. - A penetrating
portion 1213 of the delivery tube extends below a low surface of the disc likebody 1201. The protrusion extends below this lower surface a sufficient distance so that penetration of adrape 14 can occur when the delivery tube is mounted on a sealed dressing. - The delivery tube shown in
Figure 12 provides a port which can be attached to a TNP dressing to provide access for agents to the wound. To attach the delivery tube the sealing layer of the TNP dressing, referred to here as a drape, is pierced to create a small hole of suitable size to accept the small protrusion of the conduit on the bottom face of the device. Theprotector layer 1212 is removed exposing the pressure sensitive adhesive layer. The device is then positioned such that the protrusion aligns with the pierced hole on the sealing means and a force applied to ensure that a good seal is made with the adhesive. The delivery tube may be made of any substantially rigid material but aptly a flexible polymeric material having a typical sure hardness 50-70A eg silicone, PVC, polyurethane or the like may be utilised. Furthermore theinlet 1204 may include a fitting to allow attachment of a device such as a syringe or reservoir as will be appreciated by those skilled in the art. -
Figure 13 illustrates an alternative embodiment of the present invention similar in many respects to that shown inFigure 12 but in which thelower base portion 1300 includes a central substantiallyconical region 1301 which flares outwardly into a thinner disc-like region 1302. The thinness of thedisc region 1302 means that the delivery tube can be secured between two sealing drapes of a dressing. The top drape is illustrated asdrape 1305 which is a disc with central hole. To thisend protector paper 1303 is provided to cover a lower surface of anadhesive layer 1304 which is adhered at an a proximal end to an upper surface to the disc-like portion 1302 of the delivery tube. An upper surface of theadhesive layer 1304 is covered by thedrape 1305. Optionally thedrape 1305 may have a further film (not shown) on top of it to strengthen thedrape 1305 during assembly with the dressing. The film can be removed once thedrape 1305 is firmly in place. - In order to secure the delivery tube to a dressing a small hole is first punctured in a lower sealing layer with the peeling paper being removed and then the delivery tube urged onto the lower drape so that the
protrusion 1213 extends through the drape. The delivery tube is secured to the lower drape by the lower surface of theadhesive layer 1304. -
Figure 14 illustrates an alternative embodiment of the present invention in which adelivery tube 1400 has a lozenge shapedbase section 1401 from which anupstanding tube 1402 extends. Aside tube 1403, containingself sealing septum 1406, branches from themain tube 1402 and has anair inlet port 1404 andpathogen filter 1405. It will be appreciated that agents can be introduced through theseptum 1406 by insertion of a hypodermic needle attached to a syringe preloaded with agent as described hereinabove with respect to the previous embodiments. -
Figure 15 illustrates how thedelivery tube 1400 illustrated inFigure 14 can be located between amain drape 1501 andauxiliary drape 1502. As shown inFigure 15 the delivery tube of this embodiment tends to lie sideways against a wound site. The use of themain drape 1501 andauxiliary drape 1502, which form aflap 1503, means that the delivery tube and portions of the main and auxiliary drape are movable. This makes the covering easier to put on and can be more comfortable to a patient. In addition, rather than the delivery tube extending outwardly from a wound site, the tube will lie substantially flat so that accidental disturbance of the delivery tube is kept to a minimum. This is particularly helpful when the delivery tube is used continuously as part of a drip process. - In order to locate the
delivery tube 1400 at a wound site, theauxiliary drape 1502 is adhered to a target surface close to thewound site 1000. Anend region 1504 of theauxiliary drape 1502 is folded back to form afold line 1505. Theupper surface 1506 is adhesive and the lozenge portion of thedelivery tube 1402 can be adhered to this upper surface. Next themain drape 1501 is laid over the wound site covering theend region 1504 of the auxiliary drape. Alower surface 1507 of the main drape is adhesive so that the main drape and auxiliary drape can be pinched together around the lozenge base portion of thedelivery tube 1400. As a result theflap 1503 is formed which can hingedly move around thehinge line 1505. - It will be appreciated that further passageways (not shown) can be formed through the lozenge section of the
delivery tube 1400 to provide further input and output access to the wound site. - It will be appreciated by those skilled in the art that according to embodiments of the present invention rather than a syringe or reservoir being connected to the delivery tube the delivery tube may be connected directly to an outlet of a saline drip so that the wound bed may continuously be irrigated.
- It will also be appreciated that from time to time using the syringe illustrated more clearly in
Figure 10 fluid may be drawn out from the wound bed region for sampling. - The provision of a passage through the
drape 14 or under the drape means that from time to time fluid or dry agent may be introduced into a wound site without needing to move the dressing. This means that localised pain relief and/or anti-biotics and/or wound irrigation may be introduced to a wound site without the need for regular changing of dressings. This can help prevent tissue infection, reduces cost, reduces pain to the patient and reduces the risk of patient to patient infection. It will also be appreciated that from time to time embodiments of the present invention allow wound fluid to be drawn out of the wound bed again without the need to disturb thedrape 14 covering the wound dressing thus obviating certain disadvantages associated with prior art dressings. - Embodiments of the present invention enable agent to be introduced continuously or at predetermined time intervals into a wound site or for wound fluid to be drawn from the wound site either whilst topical negative pressure wound therapy continues or in such a way that TNP can be minimised
- Throughout the description and claims of this specification, the words "comprise" and "contain" and variations of the words, for example "comprising" and "comprises", means "including but not limited to", and is not intended to (and does not) exclude other moieties, additives, components, integers or steps.
- Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.
- Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith
Claims (12)
- Apparatus for delivering at least one agent to a wound site, comprising:a drape (14, 1305,1501,1502) for covering a wound site; and a delivery tube (1005, 1202, 1400) comprising a substantially T-shaped portion (1203, 1403) comprising an outlet (1007), an agent inlet port (1006, 1204) and an air inlet port (1208, 1404); wherein the air inlet port (1208, 1204) comprises an air filter (1009, 1206, 1405) characterised in that the air inlet port (1208, 1404) allows the agent inlet port (1006, 1204) to be flushed and helps the removal of large volumes of fluid from the wound.
- The apparatus as claimed in Claim 1, further comprising:an inlet valve (1011, 1102, 1205) downstream of the agent inlet port and/or a self sealing septum (1406) on the agent inlet port.
- The apparatus as claimed in Claim 2 wherein the inlet valve comprises a pinch clamp.
- The apparatus as claimed in any one of Claims 1 to 3, further comprising:a releasable cap (1008) connected to the air inlet port.
- The apparatus as claimed in any one of Claims 1 to 4, further comprising:a syringe (1010) connectable to the agent inlet port.
- The apparatus as claimed in any one of Claims 1 to 4, further comprising:a reservoir (1100), having an outlet orifice, connectable to the agent inlet port.
- The apparatus as claimed in Claim 6, further comprising:the reservoir comprises a mechanical or electrical time release system.
- The apparatus as claimed in any one of Claims 1 to 7, further comprising:the drape comprises a port arranged to receive and seal against a portion of the delivery tube.
- The apparatus as claimed in any one of Claims 1 to 7, further comprising:a disc-like body portion (1201, 1300, 1302) extending outwardly around an outlet region of the delivery tube.
- The apparatus as claimed in Claim 9, further comprising:at least one adhesive layer (1211, 1304) on the disk-like body portion.
- The apparatus as claimed in Claim 9, further comprising:a penetrating portion (1213) extending from a lower surface of the disk-like body portion.
- The apparatus as claimed in any one of Claims 1 to 11, further comprising:a TNP system comprising a drain (1003) locatable under the drape at the wound site.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0723875.1A GB0723875D0 (en) | 2007-12-06 | 2007-12-06 | Wound management |
PCT/GB2008/051159 WO2009071948A1 (en) | 2007-12-06 | 2008-12-05 | Wound management |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2231221A1 EP2231221A1 (en) | 2010-09-29 |
EP2231221B1 true EP2231221B1 (en) | 2016-07-06 |
EP2231221B2 EP2231221B2 (en) | 2019-09-18 |
Family
ID=38983089
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08856265.7A Active EP2231221B2 (en) | 2007-12-06 | 2008-12-05 | Wound management |
Country Status (7)
Country | Link |
---|---|
US (3) | US9199014B2 (en) |
EP (1) | EP2231221B2 (en) |
AU (1) | AU2008332930B2 (en) |
CA (1) | CA2707639C (en) |
ES (1) | ES2589910T3 (en) |
GB (1) | GB0723875D0 (en) |
WO (1) | WO2009071948A1 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0224986D0 (en) | 2002-10-28 | 2002-12-04 | Smith & Nephew | Apparatus |
GB0325126D0 (en) | 2003-10-28 | 2003-12-03 | Smith & Nephew | Apparatus with heat |
US11298453B2 (en) | 2003-10-28 | 2022-04-12 | Smith & Nephew Plc | Apparatus and method for wound cleansing with actives |
GB0325129D0 (en) | 2003-10-28 | 2003-12-03 | Smith & Nephew | Apparatus in situ |
GB0723875D0 (en) | 2007-12-06 | 2008-01-16 | Smith & Nephew | Wound management |
US8298200B2 (en) | 2009-06-01 | 2012-10-30 | Tyco Healthcare Group Lp | System for providing continual drainage in negative pressure wound therapy |
US9033942B2 (en) | 2008-03-07 | 2015-05-19 | Smith & Nephew, Inc. | Wound dressing port and associated wound dressing |
GB0902816D0 (en) * | 2009-02-19 | 2009-04-08 | Smith & Nephew | Fluid communication path |
SE533726C2 (en) | 2009-04-30 | 2010-12-14 | Moelnlycke Health Care Ab | Apparatus with negative pressure for treatment of wounds |
US20100324516A1 (en) | 2009-06-18 | 2010-12-23 | Tyco Healthcare Group Lp | Apparatus for Vacuum Bridging and/or Exudate Collection |
KR101648975B1 (en) * | 2009-09-22 | 2016-08-17 | 묄른뤼케 헬스 케어 에이비 | An apparatus and method for controlling the negative pressure in a wound |
WO2011087871A2 (en) | 2009-12-22 | 2011-07-21 | Smith & Nephew, Inc. | Apparatuses and methods for negative pressure wound therapy |
USRE48117E1 (en) | 2010-05-07 | 2020-07-28 | Smith & Nephew, Inc. | Apparatuses and methods for negative pressure wound therapy |
AU2011345328B2 (en) | 2010-12-22 | 2016-03-10 | Smith & Nephew, Inc. | Apparatuses and methods for negative pressure wound therapy |
USD714433S1 (en) | 2010-12-22 | 2014-09-30 | Smith & Nephew, Inc. | Suction adapter |
DE102012214178A1 (en) * | 2012-08-09 | 2014-06-12 | Paul Hartmann Ag | Connection device for use in the negative pressure therapy of wounds |
WO2014144762A2 (en) * | 2013-03-15 | 2014-09-18 | The General Hospital Corporation | Method and apparatus for wound dressing |
EP3677291B1 (en) | 2013-05-10 | 2024-01-03 | Smith & Nephew PLC | Fluidic connector for irrigation and aspiration of wounds |
CN107073180B (en) | 2014-09-10 | 2020-06-02 | 凯希特许有限公司 | Therapeutic device with integrated fluid guide and noise attenuation |
GB201811449D0 (en) | 2018-07-12 | 2018-08-29 | Smith & Nephew | Apparatuses and methods for negative pressure wound therapy |
GB202000574D0 (en) | 2020-01-15 | 2020-02-26 | Smith & Nephew | Fluidic connectors for negative pressure wound therapy |
MX2023008082A (en) * | 2021-01-13 | 2023-08-22 | Novirad Inc | Systems and methods for percutaneous drainage. |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4573965A (en) | 1984-02-13 | 1986-03-04 | Superior Plastic Products Corp. | Device for draining wounds |
US5738656A (en) | 1993-03-02 | 1998-04-14 | Wagner; Wolfgang | Drainage apparatus and method of use |
WO2001037922A2 (en) * | 1999-11-29 | 2001-05-31 | Hill-Rom Services, Inc. | Wound treatment apparatus |
US6398767B1 (en) | 1997-05-27 | 2002-06-04 | Wilhelm Fleischmann | Process and device for application of active substances to a wound surface area |
US20030040687A1 (en) * | 2001-08-24 | 2003-02-27 | Kci Licensing, Inc | Vacuum assisted tissue treatment system |
WO2003057070A2 (en) | 2001-12-26 | 2003-07-17 | Hill-Rom Services Inc. | Vented vacuum bandage and method |
US20050085795A1 (en) | 2002-02-28 | 2005-04-21 | Lockwood Jeffrey S. | External catheter access to vacuum bandage |
WO2005115523A1 (en) | 2004-05-17 | 2005-12-08 | Applied Tissue Technologies Llc | Wound chamber with remote access portal |
WO2007062024A1 (en) * | 2005-11-21 | 2007-05-31 | Joshua David Smith | Wound care system |
Family Cites Families (265)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4117551A (en) | 1974-05-30 | 1978-09-26 | William R. Brooks | Purgeable dispensing gun for polyurethane foam and the like |
US4735606A (en) * | 1982-10-12 | 1988-04-05 | Sherwood Medical Company | Chest drainage apparatus |
US4538920A (en) | 1983-03-03 | 1985-09-03 | Minnesota Mining And Manufacturing Company | Static mixing device |
US4872450A (en) | 1984-08-17 | 1989-10-10 | Austad Eric D | Wound dressing and method of forming same |
US4767026A (en) | 1987-01-16 | 1988-08-30 | Keller Wilhelm A | Dispensing and mixing apparatus |
US4753536A (en) | 1987-03-09 | 1988-06-28 | Spehar Edward R | Dispensing mixer for the storage and mixing of separate materials |
US4771919A (en) | 1987-10-28 | 1988-09-20 | Illinois Tool Works Inc. | Dispensing device for multiple components |
US5064653A (en) | 1988-03-29 | 1991-11-12 | Ferris Mfg. Co. | Hydrophilic foam compositions |
DE3827561C1 (en) | 1988-08-13 | 1989-12-28 | Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De | |
US4969880A (en) * | 1989-04-03 | 1990-11-13 | Zamierowski David S | Wound dressing and treatment method |
US5527293A (en) * | 1989-04-03 | 1996-06-18 | Kinetic Concepts, Inc. | Fastening system and method |
SE462516B (en) | 1989-07-11 | 1990-07-09 | Paal Svedman | WOOL TAPE FOR DEEP SAAR |
US5249709A (en) | 1989-10-16 | 1993-10-05 | Plas-Pak Industries, Inc. | Cartridge system for dispensing predetermined ratios of semi-liquid materials |
FR2653438B1 (en) | 1989-10-23 | 1993-06-11 | Dow Corning Sa | EXPANDABLE SILICONE COMPOSITION AND USE THEREOF. |
DE3935818A1 (en) | 1989-10-27 | 1991-05-02 | Wolfgang Dr Neher | Washing appts. for infected wound - consists of cap fitted with nozzle for spraying cleansing solution |
EP0443262B1 (en) | 1990-02-22 | 1995-09-27 | Minnesota Mining And Manufacturing Company | Static mixing assembly |
DE69132918T2 (en) | 1990-11-27 | 2002-10-31 | American Nat Red Cross Washing | TISSUE COVER AND GROWTH FACTOR CONTAINING CONNECTIONS TO PROMOTE ACCELERATED Wounds Healing |
GB9026065D0 (en) | 1990-11-30 | 1991-01-16 | Chemence Ltd | Composition |
IT225480Y1 (en) | 1991-07-05 | 1996-11-18 | Zhermack S R L | MODULAR EQUIPMENT ESPECIALLY FOR THE DOSAGE OF MULTI-COMPONENT F LUID AND / OR PASTOUS PRODUCTS |
EP0625894A1 (en) | 1991-10-09 | 1994-11-30 | LecTec Corporation | Aqueous gel wound dressing and package |
AU2605592A (en) | 1991-10-15 | 1993-04-22 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
US5837747A (en) | 1991-10-29 | 1998-11-17 | Vivorx, Inc. | Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release |
US5636643A (en) * | 1991-11-14 | 1997-06-10 | Wake Forest University | Wound treatment employing reduced pressure |
US5645081A (en) * | 1991-11-14 | 1997-07-08 | Wake Forest University | Method of treating tissue damage and apparatus for same |
US7198046B1 (en) * | 1991-11-14 | 2007-04-03 | Wake Forest University Health Sciences | Wound treatment employing reduced pressure |
US5266326A (en) | 1992-06-30 | 1993-11-30 | Pfizer Hospital Products Group, Inc. | In situ modification of alginate |
DE69324004T3 (en) | 1992-09-26 | 2005-09-01 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | APPLICATOR FOR TISSUE ADHESIVE |
US5333760A (en) | 1992-12-28 | 1994-08-02 | Coltene/Whaledent, Inc. | Dispensing and mixing apparatus |
ES2225828T3 (en) | 1993-03-12 | 2005-03-16 | The American National Red Cross | SUPPLEMENTED FABRIC SEALANTS, PRODUCTION AND USE PROCEDURES. |
JP3579052B2 (en) | 1993-03-23 | 2004-10-20 | フォーカル,インコーポレイテッド | Apparatus for local application of polymeric material to living tissue |
EP0701456B1 (en) * | 1993-06-01 | 1998-06-03 | GUIGNARD, Mireille | Device for supplying a liquid at a determined pressure to a body cavity of a person or an animal |
EP0711181A1 (en) | 1993-07-28 | 1996-05-15 | Pfizer Inc. | Psoriasis treatment |
AU7665294A (en) | 1993-09-16 | 1995-04-03 | Sunao Kubota | Wound covering material and wound covering composition |
AU1999995A (en) | 1994-04-08 | 1995-11-10 | Atrix Laboratories, Inc. | An adjunctive polymer system for use with medical device |
GB9408545D0 (en) | 1994-04-29 | 1994-06-22 | Zyma Sa | Compositions |
WO1996000760A1 (en) | 1994-06-28 | 1996-01-11 | Tri-Point Medical Corporation | pH-MODIFIED BIOCOMPATIBLE MONOMER AND POLYMER COMPOSITIONS |
US5583114A (en) | 1994-07-27 | 1996-12-10 | Minnesota Mining And Manufacturing Company | Adhesive sealant composition |
US5609271A (en) | 1995-01-25 | 1997-03-11 | Wilhelm A. Keller | Mixer and multiple component dispensing device assembly and method for the aligned connection of the mixer to the multiple component dispensing device |
US5918772A (en) | 1995-03-13 | 1999-07-06 | Wilhelm A. Keller | Bayonet fastening device for the attachment of an accessory to a multiple component cartridge or dispensing device |
WO1996040174A1 (en) | 1995-06-07 | 1996-12-19 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
US5785679A (en) | 1995-07-19 | 1998-07-28 | Endotex Interventional Systems, Inc. | Methods and apparatus for treating aneurysms and arterio-venous fistulas |
US5660823A (en) | 1995-10-11 | 1997-08-26 | Isp Investments Inc. | Fast drying, film forming iodine release solution |
US5776193A (en) | 1995-10-16 | 1998-07-07 | Orquest, Inc. | Bone grafting matrix |
GB9523253D0 (en) * | 1995-11-14 | 1996-01-17 | Mediscus Prod Ltd | Portable wound treatment apparatus |
DK0876165T3 (en) | 1995-12-18 | 2007-08-06 | Angiotech Biomaterials Corp | Crosslinked polymer compositions and methods for their preparation |
US6458889B1 (en) | 1995-12-18 | 2002-10-01 | Cohesion Technologies, Inc. | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
US5667773A (en) | 1996-03-12 | 1997-09-16 | Adolor Corporation | Film-forming compositions of antihyperalgesic opiates and method of treating hyperalgesic conditions therewith |
JP2000508001A (en) | 1996-03-15 | 2000-06-27 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | Photopolymerization induced by chemiluminescence |
WO1997042986A1 (en) | 1996-05-14 | 1997-11-20 | C. R. Bard, Inc. | Methods and products for sealing a fluid leak in a tissue |
US20040171998A1 (en) | 2000-07-21 | 2004-09-02 | Marasco Patrick V. | Isolated wound-treatment arrangement |
US6252129B1 (en) | 1996-07-23 | 2001-06-26 | Electrosols, Ltd. | Dispensing device and method for forming material |
CA2296334C (en) | 1996-07-23 | 2010-03-16 | Electrosols Ltd. | A dispensing device and method for forming material |
AU4065297A (en) | 1996-08-13 | 1998-03-06 | Eugene Bell | Collagen-based blood coagulating foams, method and devices for their delivery |
CN1246032A (en) | 1997-01-10 | 2000-03-01 | 医疗逻辑综合公司 | Cyanoacrylate compositions comprising antimicrobial agent |
AU4740597A (en) | 1997-01-10 | 1998-08-03 | Medlogic Global Corporation | Methods for draping surgical incision sites |
US7759538B2 (en) * | 1997-05-27 | 2010-07-20 | Wilhelm Fleischmann | Process and device for application of active substances to a wound surface |
GB2328443B (en) | 1997-08-21 | 2001-09-05 | Reckitt & Colmann Prod Ltd | In situ formation of pharmaceutically acceptable polymeric material |
GB9719520D0 (en) * | 1997-09-12 | 1997-11-19 | Kci Medical Ltd | Surgical drape and suction heads for wound treatment |
US6168788B1 (en) | 1997-09-26 | 2001-01-02 | Leon Wortham | Fibrin glue without fibrinogen and biosealant compositions and methods |
US5855208A (en) | 1997-10-08 | 1999-01-05 | Medlogic Global Corporation | Methods for draping surgical incision sites using a biocompatible prepolymer |
DE69810328T2 (en) | 1997-10-09 | 2003-10-16 | Flowers Park Ltd | COMPILATION OF MIXED CYANOACRYLATE ESTERS |
US6458095B1 (en) | 1997-10-22 | 2002-10-01 | 3M Innovative Properties Company | Dispenser for an adhesive tissue sealant having a housing with multiple cavities |
US5962010A (en) | 1997-11-03 | 1999-10-05 | Medlogic Global Corporation | Methods and compositions for treating dermatoses |
FR2770843B1 (en) | 1997-11-13 | 2000-01-14 | Lavipharm Lab | ASSOCIATION OF PLANT POLAR LIPID-LIPIDS, PROCESS FOR THE PREPARATION THEREOF AND ITS APPLICATIONS |
AU1923199A (en) | 1997-12-17 | 1999-07-05 | Hemodynamics, Inc. | Sealing media for surgery and wound closure |
DE19812195C2 (en) | 1998-03-19 | 2000-03-30 | Uwe Storch | Process for producing a tissue-forming implant and its use |
WO1999059670A1 (en) | 1998-05-21 | 1999-11-25 | Baxter International Inc. | Sealant applicator and method employing impulse clearing |
US6451301B1 (en) | 1998-06-08 | 2002-09-17 | Ferris Corporation | Analgesic and antinociceptive methods |
AUPP421498A0 (en) | 1998-06-18 | 1998-07-09 | Macquarie Research Limited | Method of tissue repair |
GB9813529D0 (en) | 1998-06-23 | 1998-08-19 | Courtaulds Plc | Nonwoven fabrics and their manufacture and use |
US6458109B1 (en) * | 1998-08-07 | 2002-10-01 | Hill-Rom Services, Inc. | Wound treatment apparatus |
US6152943A (en) | 1998-08-14 | 2000-11-28 | Incept Llc | Methods and apparatus for intraluminal deposition of hydrogels |
AU5560899A (en) | 1998-08-14 | 2000-03-06 | Incept Llc | Methods and apparatus for in situ formation of hydrogels |
JP4128334B2 (en) | 1998-08-18 | 2008-07-30 | バクスター・インターナショナル・インコーポレイテッド | Sealant applicator tip and application method |
PL346238A1 (en) | 1998-08-20 | 2002-01-28 | 3M Innovative Properties Co | Spray on bandage and drug delivery system |
JP4860817B2 (en) | 1998-08-26 | 2012-01-25 | ネオメンド、インク. | Compositions, systems and methods for in situ creation of chemically cross-linked mechanical barriers or coating structures |
US20050197626A1 (en) * | 1998-10-29 | 2005-09-08 | Medtronic Minimed Inc. | Fluid reservoir for use with an external infusion device |
US6899889B1 (en) | 1998-11-06 | 2005-05-31 | Neomend, Inc. | Biocompatible material composition adaptable to diverse therapeutic indications |
US7083634B2 (en) | 1998-11-12 | 2006-08-01 | Poly Med Inc | Stabilized polyester/cyanoacrylate tissue adhesive formulation |
DE59902496D1 (en) | 1998-12-23 | 2002-10-02 | Aventis Behring Gmbh | FIBRINE ADHESIVE GRANULES AND METHOD FOR THE PRODUCTION THEREOF |
DE29902666U1 (en) | 1999-02-15 | 2000-06-29 | Muehlbauer Ernst Kg | Device for dispensing mixed multicomponent materials, in particular for dental purposes |
FR2790391B1 (en) | 1999-03-02 | 2002-11-15 | Flamel Tech Sa | MEANS FOR THE PREVENTION OF POST-SURGICAL ADHESION, BASED ON CROSS-LINKED COLLAGENIC PEPTIDES |
RU2247548C2 (en) * | 1999-04-02 | 2005-03-10 | Кей Си Ай ЛАЙСЕНСИНГ, Инк. | Vacuum system for closing wounds by applying means introduced for healing the wound |
US6695823B1 (en) | 1999-04-09 | 2004-02-24 | Kci Licensing, Inc. | Wound therapy device |
ATE547136T1 (en) | 1999-04-09 | 2012-03-15 | Kci Licensing Inc | THERAPY DEVICE FOR WOUNDS |
US6312725B1 (en) | 1999-04-16 | 2001-11-06 | Cohesion Technologies, Inc. | Rapid gelling biocompatible polymer composition |
EP1048276A1 (en) | 1999-04-28 | 2000-11-02 | The Procter & Gamble Company | Method for applying a foamable movement obstruction agent to an absorbent member |
US6730299B1 (en) | 1999-07-21 | 2004-05-04 | Imedex Biomateriaux | Adhesive protein foam for surgical and/or therapeutic uses |
EP1083005A3 (en) | 1999-08-11 | 2004-12-15 | Tah Industries, Inc. | A static mixer nozzle and attachment accessory configuration |
DK1218437T3 (en) | 1999-08-27 | 2009-10-19 | Angiodevice Internat Gmbh | Preparations forming interpenetrating polymer networks for use as high-strength medical sealants |
US6394314B1 (en) | 1999-10-12 | 2002-05-28 | Discus Dental Impressions, Inc. | Double-barreled syringe with detachable locking mixing tip |
WO2001035882A1 (en) | 1999-11-15 | 2001-05-25 | The Texas A & M University System | Wound sealant formed in situ |
US6764462B2 (en) * | 2000-11-29 | 2004-07-20 | Hill-Rom Services Inc. | Wound treatment apparatus |
WO2001041779A2 (en) | 1999-12-08 | 2001-06-14 | 1149336 Ontario Inc. | Combined use of glp-2 receptor agonist and chemotherapeutic agent in treatment |
US6345776B1 (en) | 1999-12-23 | 2002-02-12 | Fomo Products Inc. | Two-component dispensing gun |
KR100721752B1 (en) | 2000-01-24 | 2007-05-25 | 쿠라레 메디카루 가부시키가이샤 | Water-swellable polymer gel and process for preparing the same |
AU2001241644A1 (en) | 2000-02-25 | 2001-09-03 | David Sierra | Foam-forming wound dressing |
GB2359755A (en) * | 2000-03-03 | 2001-09-05 | Mediplus Ltd | Apparatus for assisting wound healing |
ATE255919T1 (en) | 2000-03-31 | 2003-12-15 | Polyganics Bv | BIOMEDICAL POLYURETHANAMID, ITS PRODUCTION AND USE |
GB0011202D0 (en) * | 2000-05-09 | 2000-06-28 | Kci Licensing Inc | Abdominal wound dressing |
GB0015682D0 (en) | 2000-06-28 | 2000-08-16 | Bristol Myers Squibb Co | Sprayable wound care composition |
US6379702B1 (en) | 2000-07-05 | 2002-04-30 | Hydromer, Inc. | Gels formed by the interaction of polyvinylpyrrolidone with chitosan derivatives |
GB0017080D0 (en) | 2000-07-12 | 2000-08-30 | Bristol Myers Squibb Co | Multi layered wound dresssing |
WO2002009765A1 (en) | 2000-07-27 | 2002-02-07 | Flowers Park Limited | Methods for treating burns on mammalian skin to reduce the risk of infection and to minimize fluid loss |
GB0022084D0 (en) | 2000-09-08 | 2000-10-25 | Univ Aberdeen | Treatment of multiply antibiotic-resistant organisms |
US20020122771A1 (en) | 2000-09-23 | 2002-09-05 | Troy Holland | Spray hydrogel wound dressings |
ATE286408T1 (en) | 2000-10-23 | 2005-01-15 | Tissuemed Ltd | SELF-ADHESIVE, HYDRATEABLE MATRIX FOR THERAPEUTIC APPLICATIONS |
US20050084514A1 (en) | 2000-11-06 | 2005-04-21 | Afmedica, Inc. | Combination drug therapy for reducing scar tissue formation |
US6685681B2 (en) * | 2000-11-29 | 2004-02-03 | Hill-Rom Services, Inc. | Vacuum therapy and cleansing dressing for wounds |
GB2369799B (en) | 2000-12-07 | 2004-07-07 | Johnson & Johnson Medical Ltd | Layered polyurethane materials |
US6432077B1 (en) * | 2000-12-26 | 2002-08-13 | Sensormedics Corporation | Device and method for treatment of surface infections with nitric oxide |
US6398761B1 (en) | 2001-01-19 | 2002-06-04 | Ultradent Products, Inc. | Double syringe barrels with ported delivery ends |
US7175336B2 (en) | 2001-01-26 | 2007-02-13 | Depuy Acromed, Inc. | Graft delivery system |
CA2438047A1 (en) | 2001-02-14 | 2002-08-22 | Hildegard M. Kramer | Biocompatible fleece for hemostasis and tissue engineering |
US7700819B2 (en) | 2001-02-16 | 2010-04-20 | Kci Licensing, Inc. | Biocompatible wound dressing |
US7763769B2 (en) | 2001-02-16 | 2010-07-27 | Kci Licensing, Inc. | Biocompatible wound dressing |
US6695824B2 (en) | 2001-04-16 | 2004-02-24 | The United States Of America As Represented By The Secretary Of The Army | Wound dressing system |
US7108683B2 (en) * | 2001-04-30 | 2006-09-19 | Kci Licensing, Inc | Wound therapy and tissue management system and method with fluid differentiation |
US7645269B2 (en) | 2001-04-30 | 2010-01-12 | Kci Licensing, Inc. | Gradient wound treatment system and method |
WO2002094256A1 (en) | 2001-05-23 | 2002-11-28 | Debatosh Datta | Lysine and/or analogues and/or polymers thereof for promoting wound healing and angiogenesis |
US6547467B2 (en) | 2001-08-29 | 2003-04-15 | Closure Medical Corporation | Microapplicators, delivery systems and methods for adhesives and sealants |
EP1306123A1 (en) | 2001-10-24 | 2003-05-02 | Karlheinz Reiber | Applicator |
WO2003041686A2 (en) | 2001-11-14 | 2003-05-22 | Medlogic Global Limited | Improved therapy for topical diseases |
US6648862B2 (en) * | 2001-11-20 | 2003-11-18 | Spheric Products, Ltd. | Personally portable vacuum desiccator |
CN1291761C (en) | 2002-03-04 | 2006-12-27 | 新技术国际交流株式会社 | Closed cell culture system |
US6732887B2 (en) | 2002-03-26 | 2004-05-11 | Ultradent Products, Inc. | Two-part composition syringe delivery system |
DE10233051A1 (en) | 2002-07-19 | 2004-02-05 | Coltène/Whaledent GmbH + Co. KG | Dispensing system for fluid substances |
WO2005017000A1 (en) | 2003-07-31 | 2005-02-24 | Cambridge Polymer Group | Systems and methods for controlling and forming polymer gels |
AU2003257180A1 (en) | 2002-08-06 | 2004-02-23 | Matrix Medical, Llc | Biocompatible phase invertable proteinaceous compostions and methods for making and using the same |
US20040033466A1 (en) | 2002-08-15 | 2004-02-19 | Kerr Corporation | Single dose dental restorative material delivery system and method |
US6979324B2 (en) * | 2002-09-13 | 2005-12-27 | Neogen Technologies, Inc. | Closed wound drainage system |
US7625362B2 (en) | 2003-09-16 | 2009-12-01 | Boehringer Technologies, L.P. | Apparatus and method for suction-assisted wound healing |
US7815616B2 (en) | 2002-09-16 | 2010-10-19 | Boehringer Technologies, L.P. | Device for treating a wound |
US7862831B2 (en) | 2002-10-09 | 2011-01-04 | Synthasome, Inc. | Method and material for enhanced tissue-biomaterial integration |
US7094212B2 (en) | 2002-10-11 | 2006-08-22 | Ossur Hf | Rigid dressing |
GB2394418B (en) | 2002-10-25 | 2007-01-31 | Johnson & Johnson Medical Ltd | Fluid wound dressing |
GB0224986D0 (en) * | 2002-10-28 | 2002-12-04 | Smith & Nephew | Apparatus |
DE10258954A1 (en) | 2002-12-16 | 2004-07-08 | Langer, Hans-Georg | Bleeding wound care |
US6951553B2 (en) * | 2002-12-31 | 2005-10-04 | Kci Licensing, Inc | Tissue closure treatment system and method with externally-applied patient interface |
GB0300625D0 (en) | 2003-01-10 | 2003-02-12 | Bristol Myers Squibb Co | Wound dressing |
EP1440737A1 (en) | 2003-01-24 | 2004-07-28 | Mixpac Systems AG | Dispensing applicator for at least two components |
US20070141101A1 (en) | 2003-04-10 | 2007-06-21 | The Trustees Of Boston University | Method for stimulating angiogenesis and wound healing |
US20100210986A1 (en) | 2003-07-22 | 2010-08-19 | Sanders T Blane | Negative pressure wound treatment dressings and systems |
US7129210B2 (en) | 2003-07-23 | 2006-10-31 | Covalent Medical, Inc. | Tissue adhesive sealant |
US7785584B2 (en) | 2003-08-13 | 2010-08-31 | Healthpoint, Ltd. | Ointment wound spray |
AU2004265031B2 (en) | 2003-08-14 | 2011-03-10 | 3M Deutschland Gmbh | Capsule for two-component materials |
JP2007502697A (en) | 2003-08-21 | 2007-02-15 | ミックスパック システムズ アーゲー | Apparatus and method for transferring, mixing and dispensing components |
US20070004896A1 (en) | 2003-08-27 | 2007-01-04 | Taogosei Co., Ltd. | Active energy radiation hardenable skin plaster composition and skin plaster |
GB0325120D0 (en) * | 2003-10-28 | 2003-12-03 | Smith & Nephew | Apparatus with actives |
GB0325126D0 (en) * | 2003-10-28 | 2003-12-03 | Smith & Nephew | Apparatus with heat |
GB0409443D0 (en) | 2004-04-28 | 2004-06-02 | Smith & Nephew | Apparatus |
GB0325130D0 (en) | 2003-10-28 | 2003-12-03 | Smith & Nephew | Apparatus with scaffold |
CA2556151C (en) | 2004-02-13 | 2013-07-02 | Bristol-Myers Squibb Company | Multi layered wound dressing |
GB0403406D0 (en) | 2004-02-17 | 2004-03-24 | Biotransys Ltd | Preparation of carriers for drug delivery and other therapeutic applications |
US7754937B2 (en) | 2004-03-18 | 2010-07-13 | Boehringer Technologies, L.P. | Wound packing material for use with suction |
US7790945B1 (en) | 2004-04-05 | 2010-09-07 | Kci Licensing, Inc. | Wound dressing with absorption and suction capabilities |
US8062272B2 (en) * | 2004-05-21 | 2011-11-22 | Bluesky Medical Group Incorporated | Flexible reduced pressure treatment appliance |
US7753894B2 (en) * | 2004-04-27 | 2010-07-13 | Smith & Nephew Plc | Wound cleansing apparatus with stress |
GB0508531D0 (en) * | 2005-04-27 | 2005-06-01 | Smith & Nephew | Sai with ultrasound |
AU2004320265B2 (en) | 2004-05-27 | 2011-03-03 | University Of Pittsburgh | Medical adhesive and methods of tissue adhesion |
US20050281806A1 (en) | 2004-06-16 | 2005-12-22 | Collegium Pharmaceutical, Inc., Delaware | Compositions for topical enzymatic debridement |
US8119160B2 (en) | 2004-06-29 | 2012-02-21 | Ethicon, Inc. | Hemostatic compositions and devices |
EP1773415A1 (en) | 2004-06-30 | 2007-04-18 | Covalon Technologies Inc. | Non-adhesive hydrogels |
WO2006005206A1 (en) | 2004-07-08 | 2006-01-19 | Mixpac Systems Ag | Dispensing system comprising a syringe or cartridge, a closing cap and a mixer |
AU2005268929A1 (en) | 2004-08-03 | 2006-02-09 | Royal College Of Surgeons In Ireland | Phenytoin formulations, and uses thereof in wound healing |
US7497484B2 (en) * | 2004-08-11 | 2009-03-03 | Smiths Medical Asd, Inc. | Medical coupling system |
ES2246726B2 (en) | 2004-08-12 | 2007-11-01 | Universitat Politecnica De Catalunya | SELF-FRAGABLE AND INJECTABLE CALCIUM PHOSPHATE FOAM |
EP1796602A4 (en) | 2004-09-17 | 2016-10-19 | Angiotech Pharm Inc | Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use |
GB2418144A (en) * | 2004-09-17 | 2006-03-22 | Psimedica Ltd | Medical device for delivery of beneficial substance |
US8790632B2 (en) | 2004-10-07 | 2014-07-29 | Actamax Surgical Materials, Llc | Polymer-based tissue-adhesive form medical use |
US7717313B2 (en) | 2004-10-18 | 2010-05-18 | Tyco Healthcare Group Lp | Surgical apparatus and structure for applying sprayable wound treatment material |
EP2111804B1 (en) | 2004-10-18 | 2018-12-05 | Covidien LP | Surgical apparatus and structure for applying sprayable wound treatment material |
CA2586437C (en) * | 2004-11-05 | 2014-07-08 | Bristol-Myers Squibb Company | Vacuum wound dressing |
DE102004056456A1 (en) * | 2004-11-23 | 2006-05-24 | Eugen Malamutmann | Treatment device for wounds |
WO2008133918A1 (en) | 2007-04-24 | 2008-11-06 | Rutgers, The State University Of New Jersey | Dressing compositions and methods |
GB0501719D0 (en) | 2005-01-28 | 2005-03-02 | Green Bruce P | Sterilant system |
US20060173514A1 (en) | 2005-02-02 | 2006-08-03 | Advanced Photodynamic Technologies, Inc. | Wound treatment device for photodynamic therapy and method of using same |
GB0505909D0 (en) | 2005-03-23 | 2005-04-27 | Univ Leeds | Formulations |
US7635343B2 (en) | 2005-04-21 | 2009-12-22 | Arteriocyte Medical Systems, Inc. | Fluid dispenser |
US9162005B2 (en) | 2005-04-25 | 2015-10-20 | Arch Biosurgery, Inc. | Compositions for prevention of adhesions and other barrier applications |
KR20100102750A (en) | 2005-04-25 | 2010-09-24 | 메사추세츠 인스티튜트 오브 테크놀로지 | Compositions and methods for promoting hemostasis and other physiological activities |
US8061917B2 (en) | 2005-06-10 | 2011-11-22 | Medlogic Global Limited | Liquid applicator and method of use |
US7438705B2 (en) * | 2005-07-14 | 2008-10-21 | Boehringer Technologies, L.P. | System for treating a wound with suction and method detecting loss of suction |
US7569742B2 (en) | 2005-09-07 | 2009-08-04 | Tyco Healthcare Group Lp | Self contained wound dressing with micropump |
CN101257938A (en) | 2005-09-07 | 2008-09-03 | 泰科保健集团有限合伙公司 | Wound dressing with vacuum reservoir |
JP4919461B2 (en) | 2005-11-28 | 2012-04-18 | 日本コヴィディエン株式会社 | Medical stopcock |
WO2007073607A1 (en) | 2005-12-29 | 2007-07-05 | Sulzer Mixpac Ag | Dispensing device for single use |
US7896823B2 (en) | 2006-01-17 | 2011-03-01 | Theranova, Llc | Method and apparatus for treating wound using negative pressure therapy |
JP5479739B2 (en) | 2006-02-01 | 2014-04-23 | サムヤン バイオファーマシューティカルズ コーポレイション | Anti-adhesion composition |
US20070185463A1 (en) | 2006-02-07 | 2007-08-09 | Tyco Heal Thcare Group Lp | Surgical wound dressing |
US20090246292A1 (en) | 2006-02-21 | 2009-10-01 | Syntopix Limited | Antimicrobial formulations comprising a quinone and a copper salt |
ATE540764T1 (en) | 2006-02-24 | 2012-01-15 | Sulzer Mixpac Ag | DISPENSING DEVICE FOR A DUAL SYRINGE |
US8074843B2 (en) | 2006-03-01 | 2011-12-13 | Medmix Systems Ag | Two-part double syringe |
EP1988942B1 (en) | 2006-03-01 | 2011-07-27 | FMC Biopolymer AS | Gelled composite |
US9456860B2 (en) | 2006-03-14 | 2016-10-04 | Kci Licensing, Inc. | Bioresorbable foaming tissue dressing |
US8267918B2 (en) | 2006-03-14 | 2012-09-18 | Kci Licensing, Inc. | System and method for percutaneously administering reduced pressure treatment using a flowable manifold |
US7747319B2 (en) * | 2006-03-17 | 2010-06-29 | Zoll Medical Corporation | Automated resuscitation device with ventilation sensing and prompting |
US7854923B2 (en) | 2006-04-18 | 2010-12-21 | Endomedix, Inc. | Biopolymer system for tissue sealing |
US7779625B2 (en) | 2006-05-11 | 2010-08-24 | Kalypto Medical, Inc. | Device and method for wound therapy |
US7615036B2 (en) * | 2006-05-11 | 2009-11-10 | Kalypto Medical, Inc. | Device and method for wound therapy |
US20070276195A1 (en) | 2006-05-12 | 2007-11-29 | Kci Licensing, Inc. | Systems and methods for wound area management |
US20070276309A1 (en) | 2006-05-12 | 2007-11-29 | Kci Licensing, Inc. | Systems and methods for wound area management |
US7779825B2 (en) * | 2006-05-19 | 2010-08-24 | Estrate Evan A | High capacity paintball hoppers and loaders and paintball feeder combinations with quick disconnect, permanent and integral connection configurations |
WO2007139812A2 (en) | 2006-05-23 | 2007-12-06 | Dow Corning Corporation | Novel silicone film former for delivery of actives |
US8025650B2 (en) | 2006-06-12 | 2011-09-27 | Wound Care Technologies, Inc. | Negative pressure wound treatment device, and methods |
US20080060550A1 (en) | 2006-09-12 | 2008-03-13 | Macdonald Gavin | Color changing skin sealant with co-acid trigger |
US8725528B2 (en) | 2006-09-19 | 2014-05-13 | Kci Licensing, Inc. | System and method for managing history of patient and wound therapy treatment |
US7876546B2 (en) | 2006-09-19 | 2011-01-25 | Kci Licensing Inc. | Component module for a reduced pressure treatment system |
US20100030132A1 (en) * | 2006-09-28 | 2010-02-04 | Jeffrey Niezgoda | Apparatus and method for wound, cavity, and bone treatment |
DE102006047041A1 (en) | 2006-10-02 | 2008-04-10 | Birgit Riesinger | Areal absorbent body |
SE0602064L (en) | 2006-10-03 | 2008-04-04 | Moelnlycke Health Care Ab | Wound dressing with pressure distributing hose inlet |
CA2664285A1 (en) | 2006-10-03 | 2008-07-10 | Arsenal Medical, Inc. | Articles and methods for tissue repair |
US20080243096A1 (en) * | 2006-10-05 | 2008-10-02 | Paul Svedman | Device For Active Treatment and Regeneration of Tissues Such as Wounds |
US7387432B2 (en) | 2006-10-11 | 2008-06-17 | Meditech International Ltd.-Samoa | Slidable securing device for a mixer to allow communication between a mixer housing and a mixer inlet portion of the mixer |
US7910135B2 (en) | 2006-10-13 | 2011-03-22 | Uluru Inc. | Hydrogel wound dressing and biomaterials formed in situ and their uses |
ATE494914T1 (en) | 2006-11-07 | 2011-01-15 | Hartmann Paul Ag | MULTI-LAYER ABSORBENT WOUND DRESSING WITH A HYDROPHILIC WOUND CONTACT LAYER |
SG175690A1 (en) | 2006-11-09 | 2011-11-28 | Kci Licensing Inc | Porous bioresorbable dressing conformable to a wound and methods of making same |
US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
WO2009007785A2 (en) | 2006-11-14 | 2009-01-15 | Foamix Ltd. | Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses |
JP5581056B2 (en) | 2006-12-15 | 2014-08-27 | ライフボンド リミテッド | Gelatin-transglutaminase hemostatic dressing and sealant |
US8267908B2 (en) | 2007-02-09 | 2012-09-18 | Kci Licensing, Inc. | Delivery tube, system, and method for storing liquid from a tissue site |
BRPI0806222B8 (en) | 2007-02-09 | 2021-06-22 | Kci Licensing Inc | breathable dressing for tissue treatment |
CA2679027C (en) | 2007-02-22 | 2016-05-03 | Pluromed, Inc. | Use of reverse thermosensitive polymers to control biological fluid flow following a medical procedure |
US7646269B2 (en) * | 2007-03-07 | 2010-01-12 | Eaton Corporation | Electrical switching apparatus, and conductor assembly and shunt assembly therefor |
JP5172185B2 (en) | 2007-03-22 | 2013-03-27 | 株式会社ジーシー | Mixing chip |
US8506508B2 (en) | 2007-04-09 | 2013-08-13 | Covidien Lp | Compression device having weld seam moisture transfer |
US8092837B2 (en) | 2007-04-27 | 2012-01-10 | Biomet Manufacturing Corp | Fibrin based glue with functionalized hydrophilic polymer protein binding agent |
EP2144643B8 (en) | 2007-05-10 | 2020-12-30 | 3M Innovative Properties Company | Reduced pressure wound dressing having a wound contact surface with protrusions |
CN101678201B (en) | 2007-05-22 | 2012-12-26 | 美德乐控股公司 | Drainage tube unit |
SE531259C2 (en) | 2007-06-27 | 2009-02-03 | Moelnlycke Health Care Ab | Device for treating reduced pressure ulcers |
US7790946B2 (en) | 2007-07-06 | 2010-09-07 | Tyco Healthcare Group Lp | Subatmospheric pressure wound therapy dressing |
DE102007049429A1 (en) | 2007-08-03 | 2009-02-05 | Birgit Riesinger | Wound care articles comprising superabsorbent polymers in fiber and / or yarn form |
WO2009019229A2 (en) | 2007-08-03 | 2009-02-12 | Birgit Riesinger | Wound care article having at least one layer comprising superabsorbent polymers, and a layer comprising a soft foam material |
GB2452720A (en) | 2007-09-11 | 2009-03-18 | Ethicon Inc | Wound dressing with an antimicrobial absorbent layer and an apertured cover sheet |
WO2009038783A1 (en) | 2007-09-19 | 2009-03-26 | Surmodics, Inc. | Biocompatible foams, systems, and methods |
WO2009042514A1 (en) | 2007-09-25 | 2009-04-02 | Integra Lifesciences Corporation | Flowable wound matrix and its preparation and use |
WO2009047524A2 (en) | 2007-10-10 | 2009-04-16 | Talley Group Limited | Medical apparatus for use in negative pressure wound therapy |
US20090098073A1 (en) | 2007-10-12 | 2009-04-16 | Macdonald John Gavin | Phase change visual indicating composition |
US20090104252A1 (en) | 2007-10-19 | 2009-04-23 | Scar Consultants, Llc | Wound dressing for improving scarring |
US20090123569A1 (en) | 2007-11-08 | 2009-05-14 | Macdonald John Gavin | Coverage indicating technology for skin sealants using tannates |
WO2009062327A1 (en) | 2007-11-13 | 2009-05-22 | Medela Holding Ag | Wound drainage covering |
GB0722820D0 (en) * | 2007-11-21 | 2008-01-02 | Smith & Nephew | Vacuum assisted wound dressing |
WO2009067711A2 (en) * | 2007-11-21 | 2009-05-28 | T.J. Smith & Nephew, Limited | Suction device and dressing |
WO2009073401A2 (en) | 2007-11-28 | 2009-06-11 | The Polymer Technology Group Inc. | Silicone hydrogels for tissue adhesives and tissue dressing applications |
GB0723872D0 (en) * | 2007-12-06 | 2008-01-16 | Smith & Nephew | Apparatus for topical negative pressure therapy |
GB0723875D0 (en) | 2007-12-06 | 2008-01-16 | Smith & Nephew | Wound management |
US8545467B2 (en) | 2007-12-07 | 2013-10-01 | Medela Holding Ag | Wound cover connecting device |
SE531853C2 (en) | 2007-12-18 | 2009-08-25 | Moelnlycke Health Care Ab | Transparent film dressing for protection of skin surrounding a wound |
EP2227263A2 (en) | 2007-12-28 | 2010-09-15 | Kuros Biosurgery AG | Pdgf fusion proteins incorporated into fibrin foams |
BRPI0821424A2 (en) | 2007-12-31 | 2019-09-24 | Acclarent Inc | mucosal tissue dressing and method of use |
EP2247645B1 (en) | 2008-02-13 | 2017-12-06 | Hyperbranch Medical Technology, Inc. | Crosslinked polyalkyleneimine hydrogels with tunable degradation rates |
EP3718580A1 (en) | 2008-02-14 | 2020-10-07 | KCI Licensing, Inc. | Devices and methods for treatment of damaged tissue |
RU2010135033A (en) | 2008-03-05 | 2012-04-10 | КейСиАй Лайсензинг Инк. (US) | BANDING AND METHOD FOR APPLYING THE REDUCED PRESSURE TO THE FABRIC SECTION AND THE COLLECTION AND STORAGE OF THE LIQUID MEDIA FROM THE SITE OF THE FABRIC |
US8298200B2 (en) | 2009-06-01 | 2012-10-30 | Tyco Healthcare Group Lp | System for providing continual drainage in negative pressure wound therapy |
US8753670B2 (en) | 2008-03-26 | 2014-06-17 | Baxter International Inc. | Fibrin foam and process |
WO2009123720A2 (en) | 2008-04-01 | 2009-10-08 | Southeastern Medical Technologies, Llc | Methods and compositions for medical articles produced from proteinaceous compounds |
WO2009126833A2 (en) | 2008-04-09 | 2009-10-15 | Microlin, Llc | Transdermal oxygen delivery apparatus and method |
SE533170C2 (en) | 2008-04-09 | 2010-07-13 | Moelnlycke Health Care Ab | Device for treating wounds with suppression |
SE533167C2 (en) | 2008-04-09 | 2010-07-13 | Moelnlycke Health Care Ab | Device for treating wounds and means for making wound pads |
SE532493C2 (en) | 2008-05-29 | 2010-02-09 | Moelnlycke Health Care Ab | Wound dressing with two interconnected wound pads, suitable for use with compression dressings |
US8188331B2 (en) | 2008-05-30 | 2012-05-29 | Kci Licensing, Inc. | See-through, reduced-pressure dressings and systems |
BRPI0913458B8 (en) | 2008-09-18 | 2021-06-22 | Kci Licensing Inc | system for controlling inflammatory response in a patient's internal tissue field |
US8158844B2 (en) | 2008-10-08 | 2012-04-17 | Kci Licensing, Inc. | Limited-access, reduced-pressure systems and methods |
MX2011004463A (en) | 2008-10-29 | 2011-05-25 | Kci Licensing Inc | Modular, reduced-pressure, wound-closure systems and methods. |
MX2011005193A (en) | 2008-11-19 | 2011-06-01 | Kci Licensing Inc | Multi-layered support system and method thereof. |
-
2007
- 2007-12-06 GB GBGB0723875.1A patent/GB0723875D0/en not_active Ceased
-
2008
- 2008-12-05 ES ES08856265.7T patent/ES2589910T3/en active Active
- 2008-12-05 EP EP08856265.7A patent/EP2231221B2/en active Active
- 2008-12-05 US US12/746,502 patent/US9199014B2/en not_active Expired - Fee Related
- 2008-12-05 CA CA2707639A patent/CA2707639C/en not_active Expired - Fee Related
- 2008-12-05 WO PCT/GB2008/051159 patent/WO2009071948A1/en active Application Filing
- 2008-12-05 AU AU2008332930A patent/AU2008332930B2/en active Active
-
2015
- 2015-11-20 US US14/948,130 patent/US9694120B2/en active Active
-
2017
- 2017-05-10 US US15/592,067 patent/US10675392B2/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4573965A (en) | 1984-02-13 | 1986-03-04 | Superior Plastic Products Corp. | Device for draining wounds |
US5738656A (en) | 1993-03-02 | 1998-04-14 | Wagner; Wolfgang | Drainage apparatus and method of use |
US6398767B1 (en) | 1997-05-27 | 2002-06-04 | Wilhelm Fleischmann | Process and device for application of active substances to a wound surface area |
WO2001037922A2 (en) * | 1999-11-29 | 2001-05-31 | Hill-Rom Services, Inc. | Wound treatment apparatus |
US20030040687A1 (en) * | 2001-08-24 | 2003-02-27 | Kci Licensing, Inc | Vacuum assisted tissue treatment system |
WO2003057070A2 (en) | 2001-12-26 | 2003-07-17 | Hill-Rom Services Inc. | Vented vacuum bandage and method |
US20050085795A1 (en) | 2002-02-28 | 2005-04-21 | Lockwood Jeffrey S. | External catheter access to vacuum bandage |
WO2005115523A1 (en) | 2004-05-17 | 2005-12-08 | Applied Tissue Technologies Llc | Wound chamber with remote access portal |
WO2007062024A1 (en) * | 2005-11-21 | 2007-05-31 | Joshua David Smith | Wound care system |
Also Published As
Publication number | Publication date |
---|---|
AU2008332930A1 (en) | 2009-06-11 |
GB0723875D0 (en) | 2008-01-16 |
US9199014B2 (en) | 2015-12-01 |
EP2231221A1 (en) | 2010-09-29 |
US10675392B2 (en) | 2020-06-09 |
EP2231221B2 (en) | 2019-09-18 |
ES2589910T3 (en) | 2016-11-17 |
CA2707639C (en) | 2016-05-03 |
CA2707639A1 (en) | 2009-06-11 |
AU2008332930B2 (en) | 2014-06-05 |
US9694120B2 (en) | 2017-07-04 |
WO2009071948A1 (en) | 2009-06-11 |
US20170340784A1 (en) | 2017-11-30 |
US20110028917A1 (en) | 2011-02-03 |
US20160074564A1 (en) | 2016-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10675392B2 (en) | Wound management | |
US20210322665A1 (en) | Canister status determination | |
US10646624B2 (en) | Apparatus and method for topical negative pressure therapy | |
EP2185214B1 (en) | Apparatus for the provision of topical negative pressure therapy | |
WO2009019495A1 (en) | Apparatus | |
EP2190495A1 (en) | Pump pressure control |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20100629 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20111206 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602008045029 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61M0001000000 Ipc: A61M0003020000 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61M 3/02 20060101AFI20151021BHEP Ipc: A61M 1/00 20060101ALI20151021BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20160120 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 810244 Country of ref document: AT Kind code of ref document: T Effective date: 20160715 Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602008045029 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: MURGITROYD AND COMPANY, CH |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2589910 Country of ref document: ES Kind code of ref document: T3 Effective date: 20161117 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 810244 Country of ref document: AT Kind code of ref document: T Effective date: 20160706 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160706 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161006 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160706 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160706 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161106 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161007 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160706 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160706 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160706 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161107 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R026 Ref document number: 602008045029 Country of ref document: DE |
|
PLBI | Opposition filed |
Free format text: ORIGINAL CODE: 0009260 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160706 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160706 |
|
26 | Opposition filed |
Opponent name: KCI LICENSING, INC. Effective date: 20170403 |
|
PLAX | Notice of opposition and request to file observation + time limit sent |
Free format text: ORIGINAL CODE: EPIDOSNOBS2 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161006 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160706 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160706 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160706 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160706 |
|
PLBB | Reply of patent proprietor to notice(s) of opposition received |
Free format text: ORIGINAL CODE: EPIDOSNOBS3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160706 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161205 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20171122 Year of fee payment: 10 |
|
PLAB | Opposition data, opponent's data or that of the opponent's representative modified |
Free format text: ORIGINAL CODE: 0009299OPPO |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20081205 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160706 |
|
PLAB | Opposition data, opponent's data or that of the opponent's representative modified |
Free format text: ORIGINAL CODE: 0009299OPPO |
|
R26 | Opposition filed (corrected) |
Opponent name: KCI LICENSING, INC. Effective date: 20170403 |
|
R26 | Opposition filed (corrected) |
Opponent name: KCI LICENSING, INC. Effective date: 20170403 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161205 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20181010 Year of fee payment: 11 Ref country code: SE Payment date: 20181211 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20181015 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20190102 Year of fee payment: 11 Ref country code: IT Payment date: 20181220 Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PCOW Free format text: NEW ADDRESS: BUILDING 5, CROXLEY PARK HATTERS LANE, WATFORD, HERTFORDSHIRE WD18 8YE (GB) |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602008045029 Country of ref document: DE Representative=s name: MURGITROYD & COMPANY, DE Ref country code: DE Ref legal event code: R081 Ref document number: 602008045029 Country of ref document: DE Owner name: SMITH & NEPHEW PLC, WATFORD, GB Free format text: FORMER OWNER: SMITH & NEPHEW PLC, LONDON, GB |
|
PLAB | Opposition data, opponent's data or that of the opponent's representative modified |
Free format text: ORIGINAL CODE: 0009299OPPO |
|
PUAH | Patent maintained in amended form |
Free format text: ORIGINAL CODE: 0009272 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: PATENT MAINTAINED AS AMENDED |
|
R26 | Opposition filed (corrected) |
Opponent name: KCI LICENSING, INC. Effective date: 20170403 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: AELC |
|
RAP2 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: SMITH & NEPHEW PLC |
|
27A | Patent maintained in amended form |
Effective date: 20190918 |
|
AK | Designated contracting states |
Kind code of ref document: B2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R102 Ref document number: 602008045029 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20160706 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160706 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: NAV |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190918 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20191231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191205 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191231 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191231 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191231 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20201209 Year of fee payment: 13 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191206 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20181205 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211205 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230517 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20230929 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20231012 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20231010 Year of fee payment: 16 |